

Db 117 TVS 119

RESULT 10

PH0099

Ig heavy chain V region (anti-cyclosporin F) - mouse (fragment)

C/Species: Mus musculus (house mouse)

C/Date: 15-Jan-1993 #sequence_revision 15-Jan-1993 #text_change 21-Jan-2000

C/Accession: PH0099

R/Schmitter, D.; Poch, O.; Zeder, G.; Heinrich, G.F.; Kocher, H.P.; Quesniaux, V.F.J.; V Mol. Immunol. 27, 1029-1038, 1990

A/Title: Analysis of the structural diversity of monoclonal antibodies to cyclosporine.

A/Reference number: PH0087; MUID:91042649; PMID:2122240

A/Accession: PH0099

A/Molecule type: mRNA

A/Residues: 1-119 <SCH>

A/Cross-references: UNIPARC:UPI0000176B47

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

F;15-98/Domain: immunoglobulin homology <IMM>

F;31-35/Region: complementarity-determining 1

F;50-66/Region: complementarity-determining 2

F;99-106/Region: complementarity-determining 3

Query Match 39.3%; Score 501; DB 2; Length 119;

Best Local Similarity 80.7%; Pred. No. 1.7e-26;

Matches 96; Conservative 11; Mismatches 10; Indels 2; Gaps 1;

QY 2 QVQLQSGPELEKPGASVKLSCKASGYSFTGYTMNWVKQSHGKSLIEWIGLITPYNGASSY 61

1 EVQLQSGPELVEPGASMKISCKASGYSFAGYTMIMWKQSHGKSLIEWIGLINPYDGIAT 60

QY 62 NQKFRGKATLTVDKSSSTAYMDLSTLTSEDSAVVFCARGYDGRGFDYWGQGTITVTVSS 120

Db 61 NQKFKGKATLTVDKSSSTAYMDLSTLTSEDSAVVYCCARGY--YAVDYWGQGTSTVTVSS 117

RESULT 11

S26319

Ig heavy chain V region - mouse (fragment)

C/Species: Mus musculus (house mouse)

C/Date: 19-Mar-1998 #sequence_revision 19-Mar-1998 #text_change 21-Jan-2000

C/Accession: S26319

R/Stark, S.E.; Caton, A.J.

J. Exp. Med. 174, 613-624, 1991

A/Title: Antibodies that are specific for a single amino acid interchange in a protein

A/Reference number: S26309; MUID:91341421; PMID:1908510

A/Accession: S26319

A/Molecule type: mRNA

A/Residues: 1-114 <STA>

A/Cross-references: UNIPARC:UPI00001769A8; EMBL:X59172

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

F;11-94/Domain: immunoglobulin homology <IMM>

Query Match 39.2%; Score 500.5; DB 2; Length 114;

Best Local Similarity 82.6%; Pred. No. 1.8e-26;

Matches 95; Conservative 8; Mismatches 11; Indels 1; Gaps 1;

QY 6 QOSGPELEKPGASVKLSCKASGYSFTGYTMNWVKQSHGKSLIEWIGLITPYNGASSYNQKF 65

Db 1 QOSGPELVKPGASVKISCKASGYSFTGYFMNWVKQSHGKSLIEWIGRINPNVGDITFYNQKF 60

QY 66 RKGATLTVDKSSSTAYMDLSTLTSEDSAVVFCARGYDGRGFDYWGQGTITVTVSS 120

Db 61 RKGATLTVDKSSSTAHMELLSTLTSEDSAVVYCGKDGYYG-AMDYWGQGTSTVTVSS 114

RESULT 12

S29591

Ig kappa chain V region - mouse

C/Species: Mus musculus (house mouse)

C/Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 21-Jan-2000

C/Accession: S29591

R/Kavaler, J.

submitted to the EMBL Data Library, April 1991

A/Reference number: S26459

A/Accession: S29591

A/Status: preliminary

A/Molecule type: mRNA

A/Residues: 1-103 <KAV>

A/Cross-references: UNIPARC:UPI0000115F57; EMBL:X59094; NID:g52227; PIDN:CAA41820.1; PI

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

F;15-88/Domain: immunoglobulin homology <IMM>

Query Match 39.1%; Score 499; DB 2; Length 103;

Best Local Similarity 93.2%; Pred. No. 2e-26;

Matches 96; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 137 IELTQSPAIMSASPGKVTMTCSASSSVSYMHVYQOKSGTSPKRWIYDTSKLASGVPGRF 196

Db 1 IVLTQSPAIMSASPGKVTMTCSASSSVSYMHVYQOKSGTSPKRWIYDTSKLASGVPARF 60

QY 197 SGSGSGNSYSLTISVVEAEDDATYYCQQWSGYPLTFGAGTKLE 239

Db 61 SGSGSGTSTLTISMEAEADATYYCQQWSNPITFGAGTKLE 103

RESULT 13

A30562

Ig kappa chain V regions (27.7.2 and 27.4b.2) - mouse

C/Species: Mus musculus (house mouse)

C/Date: 23-Mar-1989 #sequence_revision 23-Mar-1989 #text_change 21-Jan-2000

C/Accession: A30562

R/Sikder, S.K.; Borden, P.; Gruzo, F.; Akolkar, P.N.; Bhattacharya, S.B.; Morrison, S.

J. Immunol. 142, 888-893, 1989

A/Title: Amino acid substitutions in V-H CDR2 change the idiotype but not the antigen-b

A/Reference number: A30562; MUID:89110066; PMID:2464031

A/Accession: A30562

A/Status: preliminary

A/Molecule type: mRNA

A/Residues: 1-107 <SIK>

A/Cross-references: UNIPARC:UPI00001767B0

C/Superfamily: immunoglobulin V region; immunoglobulin homology

C/Keywords: heterotetramer; immunoglobulin

F;16-89/Domain: immunoglobulin homology <IMM>

Query Match 39.1%; Score 499; DB 2; Length 107;

Best Local Similarity 91.4%; Pred. No. 2.1e-26;

Matches 96; Conservative 1; Mismatches 8; Indels 0; Gaps 0;

QY 137 IELTQSPAIMSASPGKVTMTCSASSSVSYMHVYQOKSGTSPKRWIYDTSKLASGVPGRF 196

Db 2 IVLTQSPAIMSASPGKVTMTCSASSSVSYMHVYQOKSGTSPKRWIYDTSKLASGVPARF 61

QY 197 SGSGSGNSYSLTISVVEAEDDATYYCQQWSGYPLTFGAGTKLE 241

Db 62 SGSGSGTSTLTISMEAEADATYYCQQWSNPITFGGKTLEIK 106

RESULT 14

F45722

anti-glycoprotein H monoclonal antibody heavy-chain variable domain (Mab 33) - mouse (F

C/Species: Mus musculus (house mouse)

C/Date: 22-Sep-1993 #sequence_revision 18-Nov-1994 #text_change 21-Jan-2000

C/Accession: F45722

R/Simpson, J.A.; Chow, J.C.; Baker, J.; Avdalovic, N.; Yuan, S.; Au, D.; Co, M.S.; Vas

J. Virol. 67, 489-496, 1993

A/Title: Neutralizing monoclonal antibodies that distinguish three antigenic sites on i

A/Reference number: F45722; MUID:93100833; PMID:7677958

A/Accession: F45722

A/Status: preliminary; not compared with conceptual translation

A/Molecule type: nucleic acid

A/Residues: 1-120 <SIM>

A/Cross-references: UNIPARC:UPI0000176D4D

Query Match	38.9%;	Score 496.5;	DB 2;	Length 120;
Best Local Similarity	78.3%;	Pred. No. 3.5e-26;		
Matches 94;	Conservative 11;	Mismatches 14;	Indels 1;	Gaps 1;

RESULT 15
B30562

Query Match	38.9%	Score 496;	DB 2;	Length 107;
Best Local Similarity	90.5%	Pred. No. 3.3e-26;		
Matches 95; Conservative	2;	Mismatches 8;	Indels 0;	Gaps 0;

Search completed: April 3, 2006, 05:30:51
Job time : 23 secs

THIS PAGE BLANK (USPTO)

Db 236 IK 237

RESULT 2

Q65ZC8_HUMAN PRELIMINARY; PRT; 244 AA.
AC Q65ZC8;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Single-chain Fv (Fragment).
GN Name=scFv;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=97362799; PubMed=9219263; DOI=10.1038/nbt0797-629;
RA Kontermann R.E., Wing M.G., Winter G.;
RT "Complement recruitment using bispecific diabodies.";
RL Nat. Biotechnol. 15:629-631(1997).
DR EMBL; Y13057; CAA73500.1; -; mRNA.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00409; Ig; 2.
DR PROSITE; PS50835; IG_LIKE; 2.
FT NON_TER 1
FT NON_TER 244
SQ SEQUENCE 244 AA; 26127 MW; 4B1F17868338F2BF CRC64;

Query Match 61.4%; Score 783.5; DB 2; Length 244;
Best Local Similarity 61.3%; Pred. No. 6.6e-53;
Matches 149; Conservative 39; Mismatches 52; Indels 3; Gaps 2;

QY 2 QVQLQSGPELEKPGASVKLSCKASGYFTGYTMNWVKSHGKSLIEWIGLITPYNGASSY 61
Db 1 QVQLVQSGAEVKKPGDVKVSKCKASGYFTSDHYMHWRQAPGQGLEWMGWIDPNNGDTRF 60
QY 62 NQKFRGKATLTVDKSSSTAYMDLISLTSEDSAVYFCARGYDGR--GPDYWGQGTIVTVS 119
Db 61 AQRFGKRVMTTRDTISAYMEVSRRLSDDTAVYYCARSGTSAIYGMVWGQGTIVTVS 120
QY 120 SGVGGSGGGSGGGSDIELTQSPAIMSASPGKVTMTCSASSV-SYMHYQOKSGTSP 178
Db 121 SGGGGSGGGSGGGSDIQMTQSPSTLSASIGDRVITICRASEGITYHMLAWYQOKPKAP 180
QY 179 KRWIYDTSKLASGVPRFSGSGSGNSYSLTISVEAEDDATYYCQQMSGYPLTFGAGTKL 238
Db 181 KPLIYKASSLASGAPSRFSGSGSGTDTLTISLQPPDPATYYCQQYSNYPLTFGGGTKL 240
QY 239 EIK 241
Db 241 EIK 243

RESULT 3

Q65ZL2_9MURI PRELIMINARY; PRT; 487 AA.
AC Q65ZL2;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE FV/M4.
GN Name=M4-IFN-<tau>;
OS Mus sp.
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muroidae; Muridae; Murinae; Mus.
OX NCBI_TaxID=10095;

RN [1]

RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=96272580; PubMed=8688499;
RA Qi Y., Xiang J.;
RT "A genetically engineered single-gene-encoded anti-TAG72 chimeric
RT antibody secreted from myeloma cells.";
RL Hum. Antibodies Hybrids 6:161-166(1995).
DR EMBL; S82493; AAB37424.2; -; mRNA.
DR GO; GO:0003823; F:antigen binding; IEA.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003598; Ig_c2.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 2.
DR SMART; SM00409; IG; 3.
DR SMART; SM00407; IGc1; 2.
DR SMART; SM00408; IGc2; 2.
DR SMART; SM00406; IGv; 2.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; 1.
SQ SEQUENCE 487 AA; 53578 MW; C7BAB69F30555504 CRC64;

Query Match 60.5%; Score 771.5; DB 2; Length 487;
Best Local Similarity 63.5%; Pred. No. 1.3e-51;
Matches 153; Conservative 28; Mismatches 53; Indels 7; Gaps 3;

QY 2 QVQLQSGPELEKPGASVKLSCKASGYFTGYTMNWVKSHGKSLIEWIGLITPYNGASSY 61
Db 20 QVQLQSDAEIVKPGASVKISCKASGYFTFDHALHMAKQKPEQGLEWIGYISPGNDIKY 79
QY 62 NQKFRGKATLTVDKSSSTAYMDLISLTSEDSAVYFCARGYDGRGFDYWGQGTIVTVSSG 121
Db 80 NEKFRGKATLTADKSSSTAYMDLISLTSEDSAVYFCRKY--GHWGQGTIVT-GSG 133
QY 122 VGGSGGGSGGGSDIELTQSPAIMSASPGKVTMTCSASSV-SYMHYQOKSGTSPKR 180
Db 134 GGGSGGGSGGGSGGSRIMQTSPLASVSVGLVITICRASENIYNLAWYQOKGKSPQL 193
QY 181 WIDYTSKLASGVPRFSGSGSGNSYSLTISVEAEDDATYYCQQMSGYPLTFGAGTKLEI 240
Db 194 LVYATNLADGVPRFSGSGSGTGYSLKINSLSGSEDFGSIYCCQHWGTPYTFGGGTRLEI 253
QY 241 K 241
Db 254 K 254

RESULT 4

Q6KB05_MOUSE PRELIMINARY; PRT; 255 AA.
AC Q6KB05;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE ScFv B8E5 protein (Fragment).
GN Name=scFv B8E5;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=Balb/c;
RA Peter J.C., Wallukat G., Tugler J., Maurice D., Roegel J.C.,
RA Briand J.P., Hoebeke J.;
RT "Modulation of the M2 muscarinic acetylcholine receptor activity with
RT monoclonal anti-M2 receptor antibody fragments.";
RL J. Biol. Chem. 279:55697-55706(2004).
DR EMBL; AJ746180; CAG34081.1; -; Other_DNA.
DR HSSP; P01837; 1KCR.

DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00409; IG; 2.
DR SMART; SM00406; IGv; 2.
DR PROSITE; PS50835; IG LIKE; 2.
FT NON_TER 1
SQ SEQUENCE 255 AA; 27445 MW; B68BD38395DF713B CRC64;

Query Match 57.5%; Score 733.5; DB 2; Length 255;
Best Local Similarity 57.6%; Pred. No. 5.3e-49;
Matches 144; Conservative 35; Mismatches 60; Indels 11; Gaps 3;

QY 2 QVQLQSGPELEKPGASVKLSCKASGYSFTGYTMNWVKQSHGKSLIEWIGLITPYNGASSY 61
Db 1 QVQLQSGGDLVKPGSLKYSCAASGFTFSYGMWVRQPDKRLIEWATITSGSYTY 60

QY 62 NQKFRGKATLTVDKSSSTAYMDLSTLSEDSAVYFCARG---GYDGRGPDYWGQTTVTY 118
Db 61 PDSVKGRFTISRDNKNTLYLQMSLSKSEDTAMYYCARHINRYDG-AFDYWGQTTTLTV 119

QY 119 SSGVSGSGGSGGGGSDIELTQSPAIMASAPGKVTMTCSASSV-----SYMHWYQ 171
Db 120 SSGGSGSGGSGGGGSDIYMAQSPSLYSAGEKIVMSCKSSQSLNSRNQKYLAWYQ 179

QY 172 QKSGTSPKRWIYDTSKLASGVPGRFSGSGSGNSYSLTISVAEADDATYCCQWGSYPLT 231
Db 180 QKPGSPKLLIYGASTRESGVPRFTGSGSGTDTFTLTSSVQAEIDLAVYYCQNDHSYPLT 239

QY 232 FGAGTKLEIK 241
Db 240 FGAGTKLEIK 249

RESULT 5
Q921A6 MOUSE
ID Q921A6 MOUSE PRELIMINARY; PRT; 241 AA.
AC Q921A6;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Anti-CEA 79 single chain Fv (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_Taxid=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98170165; PubMed=9509426;
RA Chung J.H., Choi S.J., Kim H.J., Kim I.J., Choi I.H., Lee S.D.,
RA Yi K.S., Suh P.G., Ryu S.H., Chung H.K.;
RT "Cloning and characterization of cDNAs encoding VH and VL of a
RT monoclonal anti-CEA antibody (CEA 79) cross-reactive with NCA-95 and
RT generation of a single-chain Fv molecule (scFv).";
RL Mol. Cells 7:816-819(1997).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=91341421; PubMed=1908510; DOI=10.1084/jem.174.3.613;
RA Stark S.B., Caton A.J.;
RT "Antibodies that are specific for a single amino acid interchange in a
RT protein epitope use structurally distinct variable regions.";
RL J. Exp. Med. 174:613-624(1991).
DR EMBL; U88067; AAB48044.1; -; mRNA.
DR PIR; S19965; S19965.
DR PIR; S19967; S19967.
DR PIR; S19968; S19968.
DR PIR; S26325; S26325.
DR HSSP; P01607; IBMW.
DR Ensembl; ENSMUSG0000021155; Mus musculus.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGv; 2.

DR PROSITE; PS50835; IG LIKE; 2.
FT NON_TER 1
FT NON_TER 241
SQ SEQUENCE 241 AA; 26086 MW; 0276887248B9C771 CRC64;

Query Match 56.9%; Score 726.5; DB 2; Length 241;
Best Local Similarity 58.8%; Pred. No. 1.8e-48;
Matches 144; Conservative 34; Mismatches 56; Indels 11; Gaps 5;

QY 2 QVQLQSGPELEKPGASVKLSCKASGYSFTGYTMNWVKQSHGKSLIEWIGLITPYNGASSY 61
Db 1 QVQLQSGPELKPGETVKISCKASGYTFTDYGMMWVQAQPGKGLKMMGWINTYTGEPTY 60

QY 62 NQKFRGKATLTVDKSSSTAYMDLSTLSEDSAVYFCARGGYDGRGPDYWGQTTVTYSSG 121
Db 61 ADFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARKDL-LRYFDYWGQTTVTYSSG 119

QY 122 VGSAGSGSGGGGSDIELTQSPAIMASAPGKVTMTCSASSVS-YMHWYQKSGTSPKR 180
Db 120 GGSAGSGSGGGGSDIELTQSPSLASLGKVTITCKASQDINKYIAWYQHKPGKPRS 179

QY 181 ----WIYDTSKLASGVPGRFSGSGSGNSYSLTISVAEADDATYCCQWGSYPLTFCAGT 236
Db 180 AHTLHIY----IQPGIPIRPSFGSGGGRDYSFISINLEPEDIATYCYLHYDNLH-TFGGCT 234

QY 237 KLEIK 241
Db 235 KLEIK 239

RESULT 6
Q65ZC9 HUMAN
ID Q65ZC9 HUMAN PRELIMINARY; PRT; 240 AA.
AC Q65ZC9;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Single-chain Fv (Fragment).
GN Name=scFv;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homnidae;
OC Homo.
OX NCBI_Taxid=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=C1q/7;
RX MEDLINE=97362799; PubMed=9219263; DOI=10.1038/nbt0797-629;
RA Kontermann R.E., Wing M.G., Winter G.;
RT "Complement recruitment using bispecific diabodies.";
RL Nat. Biotechnol. 15:629-631(1997).
DR EMBL; Y13056; CAA73499.1; -; mRNA.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00409; IG; 2.
DR SMART; SM00406; IGv; 2.
DR PROSITE; PS50835; IG LIKE; 2.
FT NON_TER 1
FT NON_TER 240
SQ SEQUENCE 240 AA; 25569 MW; FDCFD3645F64B373 CRC64;

Query Match 56.3%; Score 718.5; DB 2; Length 240;
Best Local Similarity 57.4%; Pred. No. 7.3e-48;
Matches 139; Conservative 43; Mismatches 55; Indels 5; Gaps 4;

QY 2 QVQLQSGPELEKPGASVKLSCKASGYSFTGYTMNWVKQSHGKSLIEWIGLITPYNGASS- 60
Db 1 QVQLVQSGGGLVQPGSLRLSCAASGFTFSYGMHWVRQAPEGKLEWVAVIS-YDGSNKY 59

QY 61 YNOKFRGKATLTVDKSSSTAYMDLSTLSEDSAVYFCARGGYDGRGPDYWGQTTVTYSS 120
Db 60 YADSVKGRFTISRDNKNTLYLQMSLSRAEDTAIVYYCARDW--GDSLDPWGKTLTVTSS 117

QY	121	GVGSGGGGSGGGSDIELTQSPALMASPGEKVTMTCSASSSV-SYNHWYQQKSSTPK	179
		: : : : : : : : : : :	
Dd	118	GGGSGGGGSGGGSDIQMTQSPSTLSASIGDRVTTICRASEGIYRWLAWYQQKPKAPK	177
QY	180	RWTYDTSKLASGVPRFSGSGSNGSYELTISSVEAEDDATYYCQOWSGYPLTFGAGTKLE	239
		: : : : : : : : : :	
Dd	178	LLEYKASSLASRAPSRFSGSGGTDFLTLTISSLQPDPDEATYYYCQOYSNPVPLTFGGGTKLE	237
QY	240	IK 241	
Dd	238	IK 239	

RESULT	7			
ID	Q65ZQ7_9MURI	PRELIMINARY;	PRT;	248 AA.
AC	Q65ZQ7;			
DT	25-OCT-2004	(TREMBLrel. 28, Created)		
DT	25-OCT-2004	(TREMBLrel. 28, last sequence update)		
DE	25-OCT-2004	(TREMBLrel. 28, last annotation update)		
BN	B3 (Fv) -PE40	(Fragment).		
GN	Name=B3 (Fv) -PE40;			
OS	Mus sp.			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;			
OC	Muridae; Murinae; Mus.			
OX	NCBI_TaxID=10095;			
RN	[1]			
RP	NUCLEOTIDE SEQUENCE.			
RX	MEDLINE=92020904; PubMed=1924323;			
RA	Brinkmann U., Pai L.H., FitzGerald D.J., Willingham M., Pastan I.;			
RT	"B3 (Fv) -PE38KDEL, a single-chain immunotoxin that causes complete			
RT	regression of a human carcinoma in mice.";			
RL	Proc. Natl. Acad. Sci. U.S.A. 88:8616-8620 (1991).			
DR	EMBL; S57990; AAB19971.2; -; mRNA.			
DR	SMR; Q65ZQ7; 4-247.			
DR	InterPro; IPR003599; Ig.			
DR	InterPro; IPR007110; Ig_1like.			
DR	InterPro; IPR003596; Ig_v.			
DR	SMART; SM00409; IG; 2.			
DR	SMART; SM00406; IG; 2.			
DR	PROSITE; PSS0835; IG_LIKE; 2.			
FT	NON_TER	248	248	
SQ	SEQUENCE	248 AA;	26634 MW;	7A3759BA3E570950 CRC64;

	Query Match	50.5%;	Score 645;	DB 2;	Length 248;	
	Best Local Similarity	51.0%;	Pred. No. 3.9e-42;			
	Matches 126;	Conservative 41;	Mismatches 74;	Indels 6;	Gaps 1;	
QY	1 MOVOLQSGPELEKPGASVKLSCKAGSYFTGYTMVWKSHGSKLSEWIGLTIPYNCASS	60				
	: : : : : : : : : : : : : : :					
Dd	1 MDVLIVESGGGLVQPGGSLKLSCATSGFTFSDYYMWVRQTPEKRLEWAVAYISNDSSAA	60				
QY	61 YNQRFGKATLTVDKSSSTAYMDLLSITSEDASAIFYCARGYDGRGFDMYGQGTIVTSS	120				
	: : : : : : : : : : : : : : :					
Dd	61 YSDPTKGRTISRDNARNNTLYIQMRLKSEDTAISCARGLAWGAFAFYWGQGTIVTVSS	120				
QY	121 GVGGSGGGGGGGGGSDIELTQSPAIMNASPGEKVMTWCASSSV-----SYMHWYQQKS	174				
	: : : : : : : : : : :					
Dd	121 GGGSGGGGGGGGGSDYLMTQSPLSLPVSLGDQASTSCRSSQIIYHSNGNTYLEWLQKP	180				
QY	175 GTSPKRWIYDTSKLASGVPRFSGSGSGNSYSLTISSVEAEADATYYCCQOWMSGYPPLTFGA	234				
	: : :					
Dd	181 GQSPKLIITYKVSNNRFSGVPDFRFSGSGSGTDFTLKISRVEAEDLGYIYCFOGSHVFETFGS	240				
QY	235 GTKLEIK 241					
Dd	241 GTKLEIK 247					

RESULT 8
Q925S1 MOUSE

ID	Q925S1_MOUSE	PRELIMINARY;	PRT;	218 AA.
AC	Q925S1;			
DT	01-DEC-2001 (TREMBLrel. 19, Created)			
DT	01-DEC-2001 (TREMBLrel. 19, Last sequence update)			
DT	01-OCT-2003 (TREMBLrel. 25, Last annotation update)			
DE	MRP5 (Fragment).			
OS	Mus musculus (Mouse).			
OC	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;			
OC	Muridae; Murinae; Mus.			
OX	NCBI_TaxID=10090;			
RN	[1]			
RP	NUCLEOTIDE SEQUENCE.			
RC	STRAIN=BALB/c;			
RX	PubMed=11819679;			
RA	Cui D.X., Zeng G.Y., Wang F., Xu J.R., Ren D.Q., Guo Y.H., Tian F.R.,			
RA	Yan X.J., Hou Y., Su C.Z.;			
RT	"Mechanism of exogenous nucleic acids and their precursors improving			
RT	the repair of intestinal epithelium after gamma-irradiation in mice.";			
RL	World J. Gastroenterol. 6:709-717(2000).			
RN	[2]			
RP	NUCLEOTIDE SEQUENCE.			
RC	STRAIN=BALB/c;			
RA	Cui D., Zeng G., Yan X., Li X., Su C.;			
RT	"Cloning of mouse genes related to repairing of intestinal epithelium			
RT	of the irradiated mice by treatment with the intestinal RNA of mice of			
RT	the same strain.";			
RL	Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 19:71-80(2001).			
DR	EMBL; AF240168; AAK43733.1; -; mRNA.			
DR	HSSP; P01665; 1QNZ.			
DR	Ensembl; ENSMUSG0000058040; Mus musculus.			
DR	InterPro; IPR007110; Ig-like.			
DR	InterPro; IPR003596; Ig_v.			
DR	SMART; SM00406; IGV. 1.			
DR	PROSITE; PS50835; IGV_LIKE; 1.			
FT	NON TER			
FT	218			
FT	218			
SEQUENCE	218 AA; 23013 MW; 527E4FA8F7982817 CRC64;			

[illegible]

```

RESULT 9
Q92552_MOUSE
ID Q92552_MOUSE PRELIMINARY; PRT; 170 AA.
AC Q92552;
DT 01-DEC-2001 (TREMBLrel. 19, Created)
DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)
DT 01-OCT-2003 (TREMBLrel. 25, Last annotation update)
DE MRP4.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Muridae; Murinae; Mus.
NCBI_TaxID=10090;
RN [1]

```

RP NUCLEOTIDE SEQUENCE.
RC STRAIN=BALB/c;
RX PubMed=11819679;
RA Cui D.X., Zeng G.Y., Wang F., Xu J.R., Ren D.Q., Guo Y.H., Tian F.R.,
RA Yan X.J., Hou Y., Su C.Z.;
RT "Mechanism of exogenous nucleic acids and their precursors improving
the repair of intestinal epithelium after gamma-irradiation in mice.";
RL World J. Gastroenterol. 6:709-717(2000).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=BALB/c;
RA Cui D., Zeng G., Yan X., Li X., Su C.;
RT "Cloning of mouse genes related to repairing of intestinal epithelium
of the irradiated mice by treatment with the intestinal RNA of mice of
the same strain.";
RL Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 19:71-80(2001).
DR EMBL; AF240167; AAK43732.1; -; mRNA.
DR HSSP; P01751; 1A6W.
DR SMR; Q925S2; 3-124.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin domain.
SQ SEQUENCE 170 AA; 17978 MW; 5042823CC6C10F38 CRC64;

Query Match 42.6%; Score 543; DB 2; Length 170;
Best Local Similarity 66.4%; Pred. No. 2.1e-34;
Matches 101; Conservative 23; Mismatches 16; Indels 12; Gaps 2;

QY 2 QVQLQSGPELEKPGASVKLSCKASGYSFTGYTMNWVKSHGKSLIEWIGLITPYNGASSY 61
Db 3 QVQLQSGPEVVRPGVSVKISCKGSGYFTDYSMHWLNKHAQSLIEWIGLITPYDGMTNY 62
QY 62 NQKFRGKATLTVDKSSSTAYMDLSTSEDSAVYFCARGGYDGR--GFDYWGQGTITVVS 119
Db 63 NQKFKGKATMTVDKSSITAYMELARLTSDDSAIYYCARGAYYGSFYFDYWGQGTITVVS 122
QY 120 SGVGGSGGGSGGGSDIELTQSPAIMSASPG 151
Db 123 SGGGSGGGSGGGSGGSGSE-----SSSPG 144

RESULT 10
Q7TMK1 MOUSE
ID Q7TMK1_MOUSE PRELIMINARY; PRT; 470 AA.
AC Q7TMK1;
DT 01-OCT-2003 (Tremblrel. 25, Created)
DT 01-OCT-2003 (Tremblrel. 25, Last sequence update)
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)
DE Hypothetical protein A1324046.
GN Name=A1324046;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=CZECH II;
RC TISSUE=Mammary tumor metastatized to lung. MMTV-LTR/Wnt1 model.
RC Expression driven by an MMTV-LTR enhancer.;
RX MEDLINE=22386257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heide F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldi M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ustin T.B., Toshlyuk S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,

RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton B., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Boufard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=CZECH II;
RC TISSUE=Mammary tumor metastatized to lung. MMTV-LTR/Wnt1 model.
RC Expression driven by an MMTV-LTR enhancer.;
RA Strausberg R.;
RL Submitted (Aug-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC055910; AAH55910.1; -; mRNA.
DR HSSP; P01865; 1KB5.
DR GO; GO:0003823; F:antigen binding; IEA.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 1.
KW Hypothetical protein; Immunoglobulin domain.
SQ SEQUENCE 470 AA; 51728 MW; 6D90E4DF896BB090 CRC64;

Query Match 40.3%; Score 514.5; DB 2; Length 470;
Best Local Similarity 52.1%; Pred. No. 1.1e-31;
Matches 122; Conservative 19; Mismatches 46; Indels 47; Gaps 8;

QY 2 QVQLQSGPELEKPGASVKLSCKASGYSFTGYTMNWVKSHGKSLIEWIGLITPYNGASSY 61
Db 20 EVQLQSGPELVKPGASVKISCKASGYFTFTGYNMHWKQSHGKSLIEWIGLVNPSGDTISY 79
QY 62 NQKFRGKATLTVDKSSSTAYMDLSTSEDSAVYFCARGGYDGR--GFDYWGQGTITVVS 119
Db 80 NQKFKGKATLTVDKSSSTAYMELNSLTSEDSAVYFCARYYSGSYTFDVMGAGITVVS 139
QY 120 SGVGGSGGGSGGGSDIELTQSPAIMSASP-----GEKVTMTCSASSSVSMHWYQK 173
Db 140 SAT-----TTAPSVYPLVPGCGDTSGSSVTGLGV----- 169
QY 174 SGTSPK---RWIYDTSKLASGYPGRFSGSGSGNSYSLTISVEAEDATYYCQ 223
Db 170 KGYPPEPTVKWNY--GALSGVTRVSSVLQSG-FYSL--SSLVTVPSSSTWPSQ 218

RESULT 11
Q6PUA7 MOUSE
ID Q6PUA7_MOUSE PRELIMINARY; PRT; 472 AA.
AC Q6PUA7;
DT 05-JUL-2004 (Tremblrel. 27, Created)
DT 05-JUL-2004 (Tremblrel. 27, Last sequence update)
DT 05-JUL-2004 (Tremblrel. 27, Last annotation update)
DE Hypothetical protein.
GN Name=Igh-1a;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=CZECH II;
RC TISSUE=Mammary tumor metastatized to lung. MMTV-LTR/Wnt1 model.
RC Expression driven by an MMTV-LTR enhancer.;
RX MEDLINE=22386257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,

RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahney J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).

RN [2]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=Czech II;
RC TISSUE=Mammary tumor metastatized to lung. MMTV-LTR/Wnt1 model.
RC Expression driven by an MMTV-LTR enhancer.;

RA Strausberg R.;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC018535; AAH18535.1; -; mRNA.

DR HSSP; P01865; 1KB5.
DR MGI; MGI:96443; Igh-1a.
DR GO; GO:0003823; F:antigen binding; IEA.

DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.

DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; C1-set; 3.

DR SMART; SM00409; IG_2.
DR SMART; SM00407; IGc1; 3.
DR SMART; SM00406; IGV_1.

DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Hypothetical protein.

KW Hypothetical protein.
SQ SEQUENCE 472 AA; 52299 MW; 165169C23D55D4AB CRC64;

Query Match 39.4%; Score 502.5; DB 2; Length 472;

Best Local Similarity 46.1%; Pred. No. 9.8e-31;
Matches 118; Conservative 26; Mismatches 59; Indels 53; Gaps 9;

QY 2 QVQLQSGPELEKPGASVKLSCKASGYSFTGYTMNWVKQSHGKSLIEWIGLITPYNGASSY 61
Db 20 EVQLQSGPELVKLTGASVSKSCASGYTFSDIYMHMWKQSHGKSLIEWIGIYIPNNGNGY 79
QY 62 NQKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARG-----GYDGRFDYWGQTTV 116
Db 80 NQKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGISYSYD-HYFDYWGQTTI 138
QY 117 TVSSGVGGSGGGGGSDIELTQSPAIMSASP-----GEKVTMTCSASSSVSYMHMY 170
Db 139 TVSSA-----KTTAPSVPLAPVCGDITGSSVTLLGCLVK---GYF--- 175
QY 171 QOKSGTSPKRWIYDTSKLASGYPRFGSGSGNSYSLTISGYEAEDDATYCCQWSGYPL 230
Db 176 -----PEPVTILTNWSSGLSSGV-HTFPALQSDLYTLSSS-----VTYTSSTWPSQSI 222

QY 231 TF-----GAGTKLEIK 241
Db 223 TCNVAHPASSTKVDK 238

RESULT 12
Q4VAB6_MOUSE
ID Q4VAB6_MOUSE PRELIMINARY; PRT; 483 AA.
AC Q4VAB6;

DT 13-SEP-2005 (Tremblrel. 31, Created)
DT 13-SEP-2005 (Tremblrel. 31, Last sequence update)
DT 13-SEP-2005 (Tremblrel. 31, Last annotation update)
DE Hypothetical protein.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxId=10090;
RN [1]

RP NUCLEOTIDE SEQUENCE.
RC STRAIN=FVB/N; TISSUE=Colon;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;

RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.L., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahney J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).

RN [2]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=FVB/N; TISSUE=Colon;
RG NIH MGC Project;
RL Submitted (MAY-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC096462; AAH96462.1; -; mRNA.
KW Hypothetical protein.

KW Hypothetical protein.
SQ SEQUENCE 483 AA; 52436 MW; 368E7BEE6BDE9EF CRC64;

Query Match 38.9%; Score 497; DB 2; Length 483;
Best Local Similarity 48.5%; Pred. No. 2.7e-30;
Matches 114; Conservative 25; Mismatches 50; Indels 46; Gaps 7;

QY 2 QVQLQSGPELEKPGASVKLSCKASGYSFTGYTMNWVKQSHGKSLIEWIGLITPYNGASSY 61
Db 20 EIQHLQSGPELVKPGTSVKMSCKASGYTFNTNYMHMWKQSHGKSLIEWIGIYIPNNGATSY 79
QY 62 NQKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGYDGRFDYWGQTTVTVSSG 121
Db 80 NQKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGDLRTGLFDYWGQTTTLTVSS- 138
QY 122 VGSAGGGGGGGGGSDIELTQSPAIM-----SASPEKVTMTCSASSSVSYMHMYQOKSGT 176
Db 139 -----EPAREPTIYPLTFPQALSSDPVILIGC-----LIHDY-FPSGT 174
QY 177 SPKRW-----IYDTSKLASGYPRFGSGSGNSYSLTISGYEAEDDATYCC 222
Db 175 MNVTWKGSKDITTVNFPALASG--GRYTMSS-----QLTLPAVECPGEGSVKC 222

RESULT 13
Q8K1F0_MOUSE
ID Q8K1F0_MOUSE PRELIMINARY; PRT; 112 AA.
AC Q8K1F0;
DT 01-OCT-2002 (Tremblrel. 22, Created)
DT 01-OCT-2002 (Tremblrel. 22, Last sequence update)
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)
DE Anti-VIpage light chain variable region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=BAHB/C; TISSUE=Hyperimmunized spleen;
RA Zhou Y.-X., Taguchi H., Planque S., Kari S., Nishiyama Y., Paul S.;
RL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=2499887;
RA Baccala R., Quang T.V., Gilbert M., Ternynck T., Avrameas S.;
RT "Two murine natural polyreactive autoantibodies are encoded by
RT nonmutated germ-line genes.";
RL Proc. Natl. Acad. Sci. U.S.A. 86:4624-4628 (1989).
DR EMBL; AF516285; AAM64203.1; -, Genomic_DNA.
DR PIR; A33933; A33933.
DR PIR; PC4405; PC4405.
DR HSSP; P01837; 1ORQ.
DR SMR; Q8K1F0; 3-112.
DR Ensembl; ENSMUSG0000062047; Mus musculus.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 112
SQ SEQUENCE 112 AA; 11901 MW; F6644663201AA239 CRC64;

Query Match 38.9%; Score 496; DB 2; Length 112;
Best Local Similarity 92.2%; Pred. No. 5.7e-31;
Matches 95; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 139 LTQSPAIMSASPGKVTMTCSASSVSVMHWYQOKSGTSPKRWIYDTSKLASGVPRFSG 198
DB 4 LTQSPAIMSASPGKVTMTCSASSVSVMHWYQOKSGTSPKRWIYDTSKLASGVPRFSG 63

QY 199 SGSGSGSYSLTISVVEADATYYCCQWMSGYPLTFGAGTKLEIK 241
DB 64 SGSGSGSYSLTISVTEGEDATYYCCQWMSGNPPTFGGTKLEIK 106

RESULT 14
Q58EV6_MOUSE PRELIMINARY; PRT; 235 AA.
AC Q58EV6;
DT 10-MAY-2005 (TREMBLrel. 30, Created)
DT 10-MAY-2005 (TREMBLrel. 30, Last sequence update)
DT 10-MAY-2005 (TREMBLrel. 30, Last annotation update)
DE Igk-C protein.
GN Name=Igk-C;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=FVB/N; TISSUE=Colon;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulik S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
```

```
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=FVB/N; TISSUE=Colon;
RG NIH MGC Project;
RL Submitted (MAR-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC091738; AAH91738.1; -, mRNA.
DR SMR; Q58EV6; 23-235.
DR GO; GO:0003823; F:antigen binding; IEA.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_c1.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PF07654; C1-set; 1.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGc1; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
SQ SEQUENCE 235 AA; 25719 MW; BE4E4ABDD2578252 CRC64;

Query Match 38.9%; Score 496; DB 2; Length 235;
Best Local Similarity 89.5%; Pred. No. 1.4e-30;
Matches 94; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 137 IELTQSPAIMSASPGKVTMTCSASSVSVMHWYQOKSGTSPKRWIYDTSKLASGVPRF 196
DB 24 IELTQSPAIMSASPGKVTMTCSASSVSVMHWYQOKSGTSPKRWIYDTSKLASGVPRF 83

QY 197 SGSGSGSYSLTISVVEADATYYCCQWMSGYPLTFGAGTKLEIK 241
DB 84 SGSGSGSYSLTISVMEADATYYCCQWTSNPLTFGAGTKLDLX 128

RESULT 15
Q91WR1_MOUSE PRELIMINARY; PRT; 488 AA.
AC Q91WR1;
DT 01-DEC-2001 (TREMBLrel. 19, Created)
DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)
DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)
DE Igh-VJ558 protein.
GN Name=Igh-VJ558;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=FVB/N; TISSUE=Kidney;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulik S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
```

RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalins D.E.,
RA Scherch A., Schein J.E., Jones S.J.M., Maira M.A.,
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.",
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).

Query Match	38.8%;	Score 495.5;	DB 2;	Length 488;
Best Local Similarity	49.6%;	Pred. No. 3.6e-30;		
Matches 120; Conservative	20;	Mismatches 47;	Indels 55;	Gaps 10;

```

QY      2 QVQLQQSGPELEKPGASVKLSCKASGSPFTGYTMNWVQSHGKSLIEWGLITPYNGASSY 61
      : ||||| : ||||| : ||||| : ||||| : ||||| : ||||| : ||||| : ||||| : ||||| : |||||
Db      20 EVQLQQSGPELVKPGASVKLSCKASGYTITDYYNWVWVQSHGKSLIEWIGDINPYNGGTSY 79

QY      62 NQKFRGKATLTVDKSSSTAYMDLISLTSEDSAVVYFCARG-----GYDGRGFDDYWGQGT 114
      ||||| : ||||| : ||||| : ||||| : ||||| : ||||| : ||||| : ||||| : ||||| : |||||
Db      80 NQKFRGKATLTVDKSSSTAYMDLNLNLTSDDSAVVYCARGPVYYSFSYD-RG-DYWGQGT 137

QY      115 TTVTSAGVGGSGGGSGGGSDIELTQSPAIM-----SAPGEKVTMTCSASSSVSYMEW 169
      ||||| : ||||| : ||||| : ||||| : ||||| : ||||| : ||||| : ||||| : ||||| : |||||
Db      138 LVTVSA-----EPAREPTIYPLTFPQALSSDPVILIGC-----LTHD 173

QY      170 YQOKSGTSPKRW-----IYDTSKIASGVPGRFSGSGSGNSYSLTITSSVEAEDDATY 220
      : ||||| : ||||| : ||||| : ||||| : ||||| : ||||| : ||||| : ||||| : ||||| : |||||
Db      174 Y-FPSPGTMTNWGKSGKIDITTVNFPALASG--GRYTWSS-----QLTLPAVVCPEGESV 225

QY      221 YC 222
      |
Db      226 KC 227

```

Search completed: April 3, 2006, 05:31:28
Job time : 58 secs

XX WO9928471-A2.
PN 10-JUN-1999.
XX
PD 25-NOV-1998; 98WO-US025270.
XX
PF 01-DEC-1997; 97US-0067175P.
XX
PR (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Pastan IH, Chowdhury PS;
XX
DR WPI; 1999-371123/31.
XX
DR N-PSDB; ABL57231.
XX
PT New anti-mesothelin antibodies.
XX
PS Claim 2; Fig 1; 63pp; English.
XX
CC The present sequence is the protein sequence of anti-mesothelin scFv
CC antibody SS. This single-chain antibody was produced by immunising a
CC mouse with cDNA encoding mesothelin, creating a phage library from mRNA
CC isolated from the spleen of the immunised animal, and enrichment of anti-
CC mesothelin phage over 3 rounds of panning. scFv SS is composed of a heavy
CC chain variable region (VH) joined to a light chain variable region (VL)
CC via a peptide linker. According to Kabat's classification, the VH belongs
CC to sub-group IIA and family V and the VL belongs to sub-group VI and
CC family XI. A claimed anti-mesothelin antibody binds recombinant
CC mesothelin with a dissociation constant of less than 3 x 10 power -8 M
CC and specifically binds to cells expressing mesothelin on their cell
CC surface. The antibody comprises SS scFv, the VH and VL region of SS scFv
CC or the complementarity determining regions of SS scFv. It is preferably
CC conjugated to a therapeutic agent, particularly pseudomonas exotoxin or
CC its cytotoxic fragment. The resulting immunconjugate is used in a
CC claimed method for inhibiting the growth of a malignant cell that
CC expresses mesothelin on its cell surface, especially in mesothelioma,
CC ovarian cancer, stomach cancer or squamous cell cancer. The antibody can
CC also be used to detect mesothelin in a biological sample
XX
SQ Sequence 241 AA;

Query Match 100.0%; Score 1276; DB 2; Length 241;
Best Local Similarity 100.0%; Pred. No. 1.8e-77;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MOVOLQSGPELEKPGASVKLSCKASGYFTGYTMNWVKQSHGKSLIEWIGLITPYNGASS 60
DB 1 MOVOLQSGPELEKPGASVKLSCKASGYFTGYTMNWVKQSHGKSLIEWIGLITPYNGASS 60
QY 61 YNOKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDYWGQGTIVTVSS 120
DB 61 YNOKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDYWGQGTIVTVSS 120
QY 121 GVGSGGGGGGGGGSDIELTQSPAIMSASPGKVTMTCSASSSVSYMHYVQOKSGTSPKR 180
DB 121 GVGSGGGGGGGGGSDIELTQSPAIMSASPGKVTMTCSASSSVSYMHYVQOKSGTSPKR 180
QY 181 WIYDTSKLASGVPRFSGSGSGNSYSLTSSVEAEDDATYYCCQWMSGYPLTFGAGTKLEI 240
DB 181 WIYDTSKLASGVPRFSGSGSGNSYSLTSSVEAEDDATYYCCQWMSGYPLTFGAGTKLEI 240
QY 241 K 241
DB 241 K 241

RESULT 2
ID AAB50019 standard; protein; 241 AA.
XX
AC AAB50019;
XX

DT 14-MAR-2001 (first entry)
XX
DE Antimesothelin antibody SS single-chain Fv protein.
XX
KW Mesothelin; SS antibody; single-chain Fv; scFv; cytostatic;
XX cancer therapy; ovarian cancer; mesothelioma.
XX
OS Unidentified.
XX
PN WO200073346-A1.
XX
PD 07-DEC-2000.
XX
PF 26-MAY-2000; 2000WO-US014829.
XX
PR 27-MAY-1999; 99US-0160071P.
XX
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Pastan I, Chowdhury PS;
XX
DR WPI; 2001-061517/07.
XX
PT Novel polypeptides comprising mutated antimesothelin antibody heavy or
PT light chain variable region, having greater binding affinity for the
PT antigen, useful as diagnostic and therapeutic agents for ovarian cancers.
XX
PS Disclosure; Fig 1; 70pp; English.
XX
CC The present sequence is antimesothelin antibody SS single chain Fv
CC protein. This sequence was used to generate mutant antibody heavy or
CC light chain variable regions, which have 5 times higher binding affinity
CC for mesothelin antigen than the parental antibody (the present sequence).
CC The mutant proteins of the present invention have substitution(s) in the
CC complementarity determining region (CDR). Malignant cells express
CC mesothelin on their surfaces, and so the mutant proteins of the present
CC invention can be used to target immunotoxin to cells expressing
CC mesothelin on their surface i.e. malignant cells. The mutant proteins of
CC the present invention can therefore be used to treat ovarian cancers,
CC mesotheliomas, and several other types of human cancers in which the
CC cells bear the mesothelin antigen
XX
SQ Sequence 241 AA;

Query Match 100.0%; Score 1276; DB 4; Length 241;
Best Local Similarity 100.0%; Pred. No. 1.8e-77;
Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MOVOLQSGPELEKPGASVKLSCKASGYFTGYTMNWVKQSHGKSLIEWIGLITPYNGASS 60
DB 1 MOVOLQSGPELEKPGASVKLSCKASGYFTGYTMNWVKQSHGKSLIEWIGLITPYNGASS 60
QY 61 YNOKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDYWGQGTIVTVSS 120
DB 61 YNOKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDYWGQGTIVTVSS 120
QY 121 GVGSGGGGGGGGGSDIELTQSPAIMSASPGKVTMTCSASSSVSYMHYVQOKSGTSPKR 180
DB 121 GVGSGGGGGGGGGSDIELTQSPAIMSASPGKVTMTCSASSSVSYMHYVQOKSGTSPKR 180
QY 181 WIYDTSKLASGVPRFSGSGSGNSYSLTSSVEAEDDATYYCCQWMSGYPLTFGAGTKLEI 240
DB 181 WIYDTSKLASGVPRFSGSGSGNSYSLTSSVEAEDDATYYCCQWMSGYPLTFGAGTKLEI 240
QY 241 K 241
DB 241 K 241

RESULT 3
ID ABR62132 standard; protein; 242 AA.
XX

AC	ABR62132;
XX	
DT	29-AUG-2003 (first entry)
XX	
DE	Single chain antibody sequence #SEQ ID 20.
XX	
KW	Tumour; drug delivery; ligand; cancer; carcinoma; bladder; breast;
KW	cervix; colorectum; lung; ovary; pancreas; prostate; stomach;
KW	choangiocarcinoma; gastric sarcoma; glioma; lymphoma; melanoma;
KW	multiple myeloma; osteosarcoma; head; neck; radiation; x-ray; antibody.
XX	
OS	Synthetic.
XX	
PN	WO2003028640-A2.
XX	
PD	10-APR-2003.
XX	
PF	27-SEP-2002; 2002WO-US030917.
XX	
PR	03-OCT-2001; 2001US-0328123P.
XX	
PA	(UYVA-) UNIV VANDERBILT.
XX	
PI	Hallahan DE, Qu S;
XX	
DR	WPI; 2003-421186/39.
XX	
PT	Identifying molecule that binds to irradiated tumor in a subject, by
PT	exposing tumor to ionizing radiation, administering library of diverse
PT	molecules and isolating library molecules from tumor to identify the
PT	target.

PS Claim 38; Page 107-108; 108pp; English.

CC The invention relates to a method for identifying a molecule that binds
CC an irradiated tumour in a subject. The method of the invention involves
CC exposing a tumour to ionizing radiation, administering a library of
CC diverse molecules to a subject, and isolating one or more molecules of
CC the library from the tumour. The method of the invention is useful for
CC identifying a molecule that binds an irradiated tumour in a subject e.g.
CC warm-blooded vertebrate and human, and also for tumour detection. The
CC tumour is a primary or a metastasized tumour such as carcinoma of the
CC bladder, breast, cervix, colorectum, lung, ovary, pancreas, prostate,
CC stomach, cholangiocarcinoma, gastric sarcoma, glioma, lymphoma, melanoma,
CC multiple myeloma, osteosarcoma, head and neck tumor and solid tumor. The
CC method of the invention is useful for X-ray-guided delivery of a
CC therapeutic composition, a diagnostic composition or their combinations
CC to a tumour in a subject. The current sequence represents a single chain
CC antibody sequence that was identified following in vivo panning to
CC irradiated tumours. This antibody binds platelet membrane glycoprotein
CC IIB
SQ Sequence 242 AA;
XX

Query Match	80.4%;	Score 1025.5;	DB 6;	Length 242;
Best Local Similarity	81.7%;	Pred. No. 9.7e-61;		
Matches 196;	Conservative 13;	Mismatches 30;	Indels 1;	Gaps 1;

OY	2	QVQLQQSGPELEKPGASVKLSCKASGSIPTGYTMNWKSHGKSLEWIGLITPYNGASSY	61
Dd	3	QVRLQQSGPELVKPGASVKMSCKASGTFTSYVMHWVQKPGGLEWIGITINPYNDGTKY	62
OY	62	NOKERKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDMQGCTTVTVSSG	121
Dd	63	NEKERKAALTSIDKSSSTAYMELSSLTSEDSAVYYCARGNYG-ALDYWGCTTVTVSSG	121
OY	122	VGGSGGGGSGGGSDIELTQSPAIMSAPGEKVMTCSASSSVSYMHWQOKSGTSPKRW	181
Dd	122	GGGSGGGGSGGGSDIELTQSPTIMSAPGEKVITCSASSSVSYMHWFOQKPQTSPKPW	181
OY	182	IYDTSKLASGVPRFSGSGSGNSYSLTISVEARDDATYYCOOWSGYPITFGAGTKLEIK	241
Dd	182	IYGTSNILASGVPRFSGSGSGTYSLTISMEARDAATYYCOOWSSYPLTFGGGKTLEIK	241

RESULT 4
ADT91209
ID ADT91209 standard; protein; 242 AA

DT 16-DEC-2004 (first entry)

DE Single chain variable fragment (scFv) antibody #2.

KW Tumour, benign intracranial meningioma; arteriovenous malformation;
 KW angioma; macular degeneration; melanoma; adenocarcinoma;
 KW malignant glioma; prostatic carcinoma; kidney carcinoma;
 KW bladder carcinoma; pancreatic carcinoma; thyroid carcinoma;
 KW lung carcinoma; colon carcinoma; rectal carcinoma; brain carcinoma;
 KW liver carcinoma; breast carcinoma; ovary carcinoma; angiofibroma;
 KW retrorenal fibroplasia; haemangioma; Kaposi's sarcoma;
 KW single chain variable fragment; scFv; antibody.

OS Unidentified.

PN US2004191249-A1.

PD 30-SEP-2004.

20-OCT-2003; 2003US-00689006.

PR 28-APR-2000; 2000WO-US011485.

PR 27-SEP-2002; 2002US-00259087.

PA (UYVA-) UNIV VANDERBILT

PI Hallahan DE, Mernaugh R;

DR WPI; 2004-698661/68.

DR N-PSDB; ADT91208.

PT Screening phage-displayed antibodies binding to radiation-inducible
PT neoantigen on cell, comprises contacting cell with antibodies, treating
PT cell with radiation, contacting cell with antibodies not binding to cell,
PT detecting bound antibody.

Claim 4; SEQ ID NO 20; 64pp; English.

The invention relates to a method for screening phage-displayed antibodies binding to radiation-inducible neoantigen on cell. The method involves contacting cell with antibodies, treating cell with radiation, contacting cell with antibodies not binding to cell and detecting the bound antibody. The method is useful for screening several phage-displayed antibodies for an ability to bind to a radiation-inducible neoantigen present on a cell, where the cell is tumour cell chosen from benign intracranial meningiomas, arteriovenous malformation, angioma, macular degeneration, melanoma, adenocarcinoma, malignant glioma, prostatic carcinoma, kidney carcinoma, bladder carcinoma, pancreatic carcinoma, thyroid carcinoma, lung carcinoma, colon carcinoma, rectal carcinoma, brain carcinoma, liver carcinoma, breast carcinoma, ovary carcinoma, solid tumours, solid tumour metastases, angiofibromas, retrolental fibroplasias, haemangiomas, Kaposi's sarcoma, head and neck carcinomas and their combinations or vascular endothelial cell. The present sequence is a single chain variable fragment (scFv) antibody that binds to radiation-inducible neoantigens.

Sequence 242 AA;

Query Match	80.4%	Score 1025.5;	DB 8;	Length 242;
Best Local Similarity	81.7%;	Pred. No. 9.7e-61;		
Matches 196; Conservative	13;	Mismatches 30;	Indels 1;	Gaps 1;

QY 2 QVQLQSGPELEKPGASVKLSCKASGYSTGYTMNWVQSHGKSLIEWIGLITPYNGASSY 61

Db		3 QVKLQSGPELVKPGASVVMSCAKSGYFTSYVMHWVKQEGGLEWIGYINPYNDGTRY	62
Oy		62 NQKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDYWGCTTVTVSSG	121
Db		63 NEKFKGKAALTSDKSSSTAYMELSSLTSEDSAVVYCARFGNG-ALDYWGQGTIVTVSSG	121
Oy		122 VGGSGGGGGGGGGSDIELTQSPAIMSAFGEKVMTCSASSSVSYMHWQKSQTSPKRW	181
Db		122 GGGSGGGGGGGGGSDIELTQSPTIMSAPDEKVTITCSASSSVSYMHWQKPQTSPKPW	181
Oy		182 IYDTSKIASGVBRFGSGSGSNYSLSLTISVVEAEDDATYYCQOWMSGYPLTFGAGTKLEIK	241
Db		182 IYGTSMLASGVPRFSGSGGSTSYSLSLTISMFAEDATYYCQOWSSYPITFGGCKLEIK	241
RESULT 5			
AAB47111	ID	AAB47111 standard; protein; 239 AA.	
XX	AC	AAB47111;	
XX	DT	04-JUN-2001 (first entry)	
XX	DE	BCFV 508F.	
KM		Human; prion protein; plaque forming disease; display vehicle; kuru;	
KM		aggregating protein; amyloid plaque; brain; early onset; senility;	
KM		Alzheimer's disease; late onset; pre-symptomatic; SAA amyloidosis;	
KM		hereditary Icelandic syndrome; multiple myeloma; scrapie; BSE; CJD;	
KM		bovine spongiform encephalopathy; Creutzfeldt-Jakob Disease; FFI;	
KM		Gerstmann-Straussler-Sheinker Disease; GSS; fatal familial insomnia;	
KM		antibody.	
XX		Synthetic.	
OS			
XX	FH	Key Location/Qualifiers	
FT		Domain 1..120	
FT		/note= "Heavy chain"	
FT		Region 31..35	
FT		/label= CDR1	
FT		Region 50..66	
FT		/label= CDR2	
FT		Region 99..107	
FT		/label= CDR3	
FT		Peptide 121..133	
FT		/note= "Linker"	
FT		Domain 134..239	
FT		/note= "Light chain"	
FT		Region 157..166	
FT		/label= CDR1	
FT		Region 182..188	
FT		/label= CDR2	
FT		Region 221..229	
FT		/label= CDR3	
XX			
PN		WO200118169-A2.	
XX			
PD		15-MAR-2001.	
XX			
PF		31-AUG-2000; 2000WO-IL000518.	
XX			
PR		03-SEP-1999; 99US-0152417P.	
PR		29-DEC-1999; 99US-00473653.	
PR		31-JUL-2000; 2000US-00629971.	
XX			
PA		(UYRA-) UNIV RAMOT APPLIED RES & IND DEV LTD.	
XX			
PI		Solomon B, Frenkel D, Hanan E;	
XX			
DR		WPI; 2001-244564/25.	
DR		N-PSDB; AAC85539.	
XX			
PT		Treating amyloidgenic disease such as Alzheimer's disease, BSE or CJD	

PT comprises presentation of plaque derived antigens or epitopes on a display vehicle, and introducing the vehicle into the recipient.

Example 2; Fig 11; 120pp; English.

This sequence shows scFv 508F heavy chain, linker and light chain. The scFv fragment was derived from the 508 IGM hybridoma which is generated from splenocytes of a mouse that has been immunised with a peptide corresponding to the 16 amino terminal residues of beta-A β conjugated to keyhole limpet hemocyanin used a carrier. The resultant variable chain fragments may be used in the method of the invention. Cys 96 of the VL fragment was replaced with various amino acids to see if production yield or stability were effected without having an adverse effect on its binding affinity. The invention provides an agent for treating a plaque forming disease. Antigenic polypeptides are displayed on a display vehicle and are capable of eliciting antibodies capable of disaggregating the aggregating protein and/or of preventing aggregation of the aggregating protein. This reduces formation of amyloid plaques in the brain of victims of plaque forming diseases, e.g. early onset Alzheimer's disease, late onset Alzheimer's disease, pre-symptomatic Alzheimer's disease, SAA amyloidosis, hereditary Icelandic syndrome, senility, multiple myeloma, scrapie, bovine spongiform encephalopathy (BSE), kuru, Creutzfeldt-Jakob Disease (CJD), Gerstmann-Straussler-Sheinker Disease (GSS) and fatal familial insomnia (FFI)

Sequence 239 AA:

Query Match	79.2%;	Score 1010.5;	DB 4;	Length 239;
Best Local Similarity	79.8%;	Pred. No. 9.6e-60;		
Matches 194;	Conservative 16;	Mismatches 26;	Indels 7;	Gaps 2;

[illegible]

RESULT 6

AA016066 standard; protein; 239 AA.

AC AA016066;

DT 27-FEB-2003 (first entry)

DE Human neurological/CNS disease treatment method-related protein.

AA vaccine; gene therapy; neurological disease; CNS disorder;
 KW central nervous system disorder; olfactory system; Alzheimer's disease;
 KW Creutzfeld-Jacob disease; Huntington's chorea; Parkinson's disease;
 KW viral infection of the brain; brain tumour; lysosomal storage disease;
 KW multiple sclerosis.

OS Homo sapiens.

AA WO200274243-A2.
PN

PD 26-SEP-2002.

XX 15-MAR-2002; 2002WO-US008042.
PF
XX 15-MAR-2001; 2001US-00808037.
PR
XX (UYRA-) UNIV RAMOT APPLIED RES & IND DEV LTD.
PA (MCIN/) MCINNIS P.
XX
PI Solomon B, Frenkel D;
XX
XX WPI; 2003-040542/03.
DR N-PSDB; AAL51099.
DR
XX Treating or diagnosing neurological diseases of the central nervous
PT system, e.g. Alzheimer's disease, comprises displaying a polypeptide or
PT diagnostic agent on viral display vehicle and introducing or detecting
PT the display vehicle.
XX
XX Example 2; Fig 11A; 214pp; English.
XS

The invention comprises a method for treating a neurological disease or a central nervous system (CNS) disorder. The method involves displaying a therapeutic molecule capable of treating the neurological disease or CNS disorder on a viral display vehicle. The viral display vehicle is then introduced into the olfactory system of a subject to treat the disease or disorder. The method of the invention is useful for preventing, treating and diagnosing neurological diseases or CNS disorders, such as: Alzheimer's disease; Creutzfeld-Jakob disease; Huntington's chorea; viral infections of the brain; brain tumours; lysosomal storage diseases; Parkinson's disease; and multiple sclerosis. The present amino acid sequence represents a protein which was used in the invention

Query Match	79.2%;	Score 1010.5;	DB 6;	Length 239;
Best Local Similarity	79.8%;	Pred. No. 9.6e-60;		
Matches 194;	Conservative 16;	Mismatches 26;	Indels 7;	Gaps 2;

QY	2	QVQLQDSGP	LELEKPGASV	KLSCKASGYS	FTGYTMAMV	KQSHGKSL	EWIGLIT	PYNGASSY	61
		: : : :	: : : :	: : : :	: : : :	: : : :	: : : :	: : : :	
Db	1	QVQLQDSGA	ELVRPGVSV	KISCKGSG	YTFPTDYAMH	WVKQSHAKS	LEWIGVIS	ITYYGDASY	60
QY	62	NQKPRGKAT	LTVDKSS	STAYMDL	SLTSEDS	AVVFCARG	--GYDGR	DFDYWGQ	118
		: : : :	: :	: :	: :	: :	----	----	
Db	61	NQKPRKATM	TVDDKSS	STAYMEL	ARLTSEDS	AIYYCARG	ATMSY----	FDYWGQV	116
		: :	: :	: :	: :	: :	----	----	
QY	119	SSGVGGSG	GGSGGSD	IELTQSP	AIMSAS	PGEKMT	CSASSSV	YMHWYQ	178
		: :	: :	: :	: :	: :	: :	: :	
Db	117	SSGGGSG	GGVSGSG	SDIELTQ	SPAIMSAS	PGEKMT	CSASSS	ISTMHWYQ	176
		: :	: :	: :	: :	: :	: :	: :	
QY	179	KRWIYDTS	KLASGV	PRFSG	SGSGNS	SLTIS	SVAEAD	DATYYCQ	238
		: :	: :	: :	: :	: :	: :	: :	
Db	177	KRWIYDTS	KLASGV	PARFSG	SGSGT	SYSLTIS	SMBAED	DATYYCHQ	236
		: :	: :	: :	: :	: :	: :	: :	
QY	239	EIK	241						
Db	237	EIK	239						

RESULT 7	
ADJ88113	
ID	ADJ88113 standard; protein; 239 AA.
XX	
AC	ADJ88113;
XX	
DT	06-MAY-2004 (first entry)
XX	
DE	Human beta amyloid peptide antibody (508) heavy chain protein.
XX	
KW	Neurological disease; central nervous system; CNS disorder;
KW	plaque-forming disease; Alzheimer's disease; SAA amyloidosis;
KW	hereditary Icelandic syndrome; senility; multiple myeloma; scrapie;
KW	bovine spongiform encephalopathy; BSE; kuru; Creutzfeldt-Jakob disease;

KW	CJD; Gerstmann-Strausler-Scheinker disease; GSS; fatal familial insomnia;
KW	FTI; non-plaque-forming disease; Huntington's chorea; viral infection;
KW	brain tumour; lysosomal storage disease; neurodegeneration;
KW	multiple sclerosis; vaccine; beta amyloid peptide; beta AP; antibody;
KW	human.
XX	
OS	Homo sapiens.
XX	
FH	Key
FT	Region
FT	31..35
FT	/note= "CDR1"
FT	50..66
FT	/note= "CDR2"
FT	99..107
FT	/note= "CDR3"
XX	
PN	US2004013647-A1.
XX	
PD	22-JAN-2004.
XX	
PF	11-MAR-2003; 2003US-00384788.
XX	
PR	03-SEP-1999; 99US-0152417P.
PR	29-DEC-1999; 99US-00473653.
PR	31-JUL-2000; 2000US-00629971.
PR	31-AUG-2000; 2000WO-11000518.
PR	15-MAR-2001; 2001US-00808037.
PR	07-AUG-2001; 2001US-00830954.
PR	12-APR-2002; 2002US-0371735P.
PR	06-JUN-2002; 2002US-00162889.
XX	
PA	(UYRA-) UNIV RAMOT AT TEL AVIV LTD.
XX	
PI	Solomon B, Frenkel D;
XX	
DR	WPI; 2004-108188/11.
XX	
DR	N-PSDB; ADJ88112.
PT	Treating neurological disease CNS e.g., Alzheimer's disease, by
PT	displaying therapeutic molecule capable of treating the disease on viral
PT	display vehicle which is then administered to subject through olfactory
PT	system.
XX	
PS	Example 2; SEQ ID NO 6; 68bp; English.
XX	
CC	The invention relates to a method of treating a neurological disease or
CC	disorder of the central nervous system (CNS). The method involves
CC	displaying a therapeutic molecule capable of treating the neurological
CC	disease or disorder of the CNS on a viral display vehicle and introducing
CC	viral display vehicle into a subject by applying an effective amount of
CC	the viral display vehicle displaying the therapeutic molecule to an
CC	olfactory system of the subject. The method is useful for treating a
CC	neurological disease or disorder of CNS such as a plaque-forming disease
CC	such as Alzheimer's disease, late onset Alzheimer's disease,
CC	presymptomatic Alzheimer's disease, SAA amyloidosis, hereditary Icelandic
CC	syndrome, senility, multiple myeloma, scrapie, bovine spongiform
CC	encephalopathy (BSE), kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-
CC	Streussler-Scheinker disease (GSS) or fatal familial insomnia (FFI). The
CC	method is also useful for treating a non plaque forming disease or
CC	disorder e.g. Huntington's chorea, viral infections of the brain, brain
CC	tumours, lysosomal storage diseases which cause neurodegeneration and are
CC	manifested by enzyme deficiencies and multiple sclerosis. The invention
CC	is also used in the preparation of vaccines. The present sequence is
CC	human beta amyloid peptide (beta AP) antibody heavy chain protein. This
CC	sequence is used to illustrate the method of the invention.
XX	
SQ	Sequence 239 AA;

Query Match 79.2%; Score 1010.5; DB 8; Length 239;

Best Local Similarity 79.8%; Pred. No. 9.6e-60;

Matches 194; Conservative 16; Mismatches 26; Indels 7; Gaps 2;

Db 1 QVKLQESGAELVRPGVSVKISCKGSGTFTDYAMHWKQSHAKSLEWIGVISTYYGDASY 60
QY 62 NQKFRGKATLTVDKSSSTAYMDLSTSEDSAVYFCARG--GYDGRGFDYWGQTTVTY 118
Db 61 NQKFKGATMTVDKSSSTAYMELARLTSEDSAIYYCARGATMSY----FDYWGQVTTVTY 116
QY 119 SSGVGSGGGGGGGGGSDIELTQSPAIMSASPGEKVTMTCSASSSVSYMHYQOKSGTSP 178
Db 117 SSGGGGGGGGGGGGGSDIELTQSPAIMSASPGEKVTMTCSASSSISYMHYQOKPGTSP 176
QY 179 KRWTYDTSKLASGVPRFSGSGSGNSYSLTISVVEAEDDATYCCQWMSGYPLTFGAGTKL 238
Db 177 KRWTYDTSKLASGVPARFSGSGSGTSYSLTISMEAEADATYCHQKSSYPPTFGGAKL 236
QY 239 EIK 241
Db 237 EIK 239

RESULT 8
ADV66089
ID ADV66089 standard; protein; 494 AA.

XX AC ADV66089;
XX DT 24-FEB-2005 (first entry)
XX DE Anti-CD3-anti-EpCAM bispecific single chain antibody - SEQ ID 12.
XX KW bispecific single chain antibody; epithelial cell adhesion molecule;
XX KW EpCAM; CD3; tumor; cancer; cytostatic.
XX OS Unidentified.
XX PN WO2004106383-A1.
XX PD 09-DEC-2004.
XX PF 26-MAY-2004; 2004WO-EP005687.
XX PR 31-MAY-2003; 2003EP-00012133.
XX PR 31-MAY-2003; 2003EP-00012134.
XX PA (MICR-) MICROMET AG.
XX PI Kufer P, Berry M, Offner S, Brischwein K, Wolf A, Raum T;
XX PI Kohleisen B, Lenkeri-Schuetz U, Baenerle P;
XX DR WPI; 2005-021271/02.
XX DR N-PSDB; ADV66088.
XX PT New pharmaceutical composition having a bispecific single chain antibody
XX PT construct, useful for preventing, treating or ameliorating a tumorous
XX PT disease, such as an epithelial or minimal residual cancer.
XX PS Claim 12; SEQ ID NO 12; 227pp; English.
XX CC The invention comprises a composition that contains a bispecific single
XX CC chain antibody consisting of at least two domains, where one of domains
XX CC binds to human epithelial cell adhesion molecule (EpCAM) antigen, and the
XX CC second domain binds to human CD3 antigen. The bispecific antibody
XX CC construct of the invention is useful for the prevention, treatment or
XX CC amelioration of a tumorous disease, such as an epithelial or minimal
XX CC residual cancer. The present amino acid sequence represents a bispecific
XX CC single chain antibody of the invention.

Query Match 78.7%; Score 1004; DB 9; Length 494;
Best Local Similarity 80.3%; Pred. No. 5.5e-59;
Matches 192; Conservative 17; Mismatches 30; Indels 0; Gaps 0;

QY 3 VOLQSGPELEKPGASVKLSCKASGYSTGYTMNWVKQSHGKSLEWIGLITPYNGASSYN 62
Db 2 IKLQSGAELARPGASVKMSCTSGYTFIRYTMHWKQRPQGLEWIGYINPSRGYTNYN 61
QY 63 QKFRGKATLTVDKSSSTAYMDLSTSEDSAVYFCARGGYDGRGFDYWGQTTVTYSSGV 122
Db 62 QKFKDKATLTVDKSSSTAYMQLSSLTSEDSAVYCARYYDDHYCLDYWGQTTTLTVSSGG 121
QY 123 GSGGGGGGGGGGGSDIELTQSPAIMSASPGEKVTMTCSASSSVSYMHYQOKSGTSPKRWI 182
Db 122 GSGGGGGGGGGGGSDIQLTQSPAIMSASPGEKVTMTCSASSSVSYMHYQOKSGTSPKRWI 181
QY 183 YDTSKLASGVPRFSGSGSGNSYSLTISVVEAEDDATYCCQWMSGYPLTFGAGTKLEIK 241
Db 182 YDTSKVASGVPRFSGSGSGTSYSLTISMEAEADATYCCQWSSNPLTFGAGTKLEIK 240

RESULT 9
ADV66137
ID ADV66137 standard; protein; 500 AA.

XX AC ADV66137;
XX DT 24-FEB-2005 (first entry)
XX DE Anti-CD3-anti-EpCAM bispecific single chain antibody - SEQ ID 60.
XX KW bispecific single chain antibody; epithelial cell adhesion molecule;
XX KW EpCAM; CD3; tumor; cancer; cytostatic.
XX OS Unidentified.
XX PN WO2004106383-A1.
XX PD 09-DEC-2004.
XX PF 26-MAY-2004; 2004WO-EP005687.
XX PR 31-MAY-2003; 2003EP-00012133.
XX PR 31-MAY-2003; 2003EP-00012134.
XX PA (MICR-) MICROMET AG.
XX PI Kufer P, Berry M, Offner S, Brischwein K, Wolf A, Raum T;
XX PI Kohleisen B, Lenkeri-Schuetz U, Baenerle P;
XX DR WPI; 2005-021271/02.
XX DR N-PSDB; ADV66136.
XX PT New pharmaceutical composition having a bispecific single chain antibody
XX PT construct, useful for preventing, treating or ameliorating a tumorous
XX PT disease, such as an epithelial or minimal residual cancer.
XX PS Claim 12; SEQ ID NO 60; 227pp; English.
XX CC The invention comprises a composition that contains a bispecific single
XX CC chain antibody consisting of at least two domains, where one of domains
XX CC binds to human epithelial cell adhesion molecule (EpCAM) antigen, and the
XX CC second domain binds to human CD3 antigen. The bispecific antibody
XX CC construct of the invention is useful for the prevention, treatment or
XX CC amelioration of a tumorous disease, such as an epithelial or minimal
XX CC residual cancer. The present amino acid sequence represents a bispecific
XX CC single chain antibody of the invention.

Query Match 78.7%; Score 1004; DB 9; Length 500;
Best Local Similarity 80.3%; Pred. No. 5.6e-59;
Matches 192; Conservative 17; Mismatches 30; Indels 0; Gaps 0;

QY 3 VOLQSGPELEKPGASVKLSCKASGYSTGYTMNWVKQSHGKSLEWIGLITPYNGASSYN 62
Db 2 IKLQSGAELARPGASVKMSCTSGYTFIRYTMHWKQRPQGLEWIGYINPSRGYTNYN 61


```

QY      63 QKRGKATLTVDKSSSTAYMDLLSTSEDAVYFCARGYDGRGFDYWGQTTVTVSSGV 122
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      62 QKFXDKATLTTDKSSSTAYMQLSLTSEDAVYCYARYDDHYCLDYWGQTTLTVSSG 121
QY      123 GSGSGGSGGGGSDIELTQSPAIMASPEKVTMTCSASSVSYMHVYQKSGTSPKRWI 182
      |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      122 GSGSGGSGGGGSDIQLTQSPAIMASBPGEKVTMTCRASSVSVMYVYQKSGTSPKRWI 181
QY      183 YDTSKLASGVPRFSGSGSGNSYSLTISVVEAEDDATYYCQWMSGYPLTFGAGTKLEIK 241
      |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      182 YDTSKVASGVPRFSGSGSGTYSYLTISSEAEADAATYYCQWSSNPLTFGAGTKLEIK 240

```

RESULT 10
ADV66095
ID ADV66095 standard; protein; 500 AA.

DT 24-FEB-2005 (first entry)
XX
DE Anti-CD3-anti-EpCAM bispecific single chain antibody - SEQ ID 18.
XX
KW bispecific single chain antibody; epithelial cell adhesion molecule;
KW EpCAM; CD3; tumor; cancer; cytostatic.
XX
OS Unidentified.
XX
PN WO2004106383-A1.
XX
PD 09-DEC-2004.
XX
PF 26-MAY-2004; 2004WO-EP005687.
XX
PR 31-MAY-2003; 2003BP-00012133.
PR 31-MAY-2003; 2003BP-00012134.
XX
PA (MICR-) MICROMET AG.
XX
PI Kufer P, Berry M, Offner S, Brieschwein K, Wolf A, Raum T;
PI Kohleisen B, Lenkkeri-Schuetz U, Baerle P;
XX
DR MPI; 2005-021271/02.
DR N-PSDB; ADV66094.
XX
XX
PT New pharmaceutical composition having a bispecific single chain antibody
PT construct, useful for preventing, treating or ameliorating a tumorous
PT disease, such as an epithelial or minimal residual cancer.
XX
PS Claim 12; SEQ ID NO 18; 227pp; English.
XX
CC The invention comprises a composition that contains a bispecific single
CC chain antibody consisting of at least two domains, where one of domains
CC binds to human epithelial cell adhesion molecule (EpCAM) antigen, and the
CC second domain binds to human CD3 antigen. The bispecific antibody
CC construct of the invention is useful for the prevention, treatment or
CC amelioration of a tumorous disease, such as an epithelial or minimal
CC residual cancer. The present amino acid sequence represents a bispecific
CC single chain antibody of the invention.
XX
SQ Sequence 500 AA;

Query Match	78.7%;	Score 1004;	DB 9;	Length 500;
Best Local Similarity	80.3%;	Pred. No. 5,6e-59;		
Matches 192;	Conservative 17;	Mismatches 30;	Indels 0;	Gaps 0;

QY 3 VOLDSSGPELEKPGASVKLSCKASGSFTGYTMNWKVSKHKSLEWIGILTTPYNGASSYN 62
: : : : : : : : : : : : : : : :
Db 2 IKLDSSGAELIARPGASVKMSCKTSGYTFRYTMHWKORPGGLEWIGIYNPSRGYTNN 61
QY 63 QKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVFPCARGGYDGRGFIDWGQTIVTVSSGV 122
: : : : : : : : : : : : : : : :

```

Db      62  QKFKDKATLTITDKSSSTAYMQLSSLTSEDSAVRYCARYDDHCLDYWGCGITTLTVSSGG  121
QY      123  GSGSGGGGGGGGSDIEILTQSPAIMSASPEKVTMTCSASSSVSYMHWYQOKSGTSPKRWI  182
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      122  GSGSGGGGGGGGSDIQLTQSPAIMSASPEKVTMTCSASSSVSYMHWYQOKSGTSPKRWI  181
QY      183  YDTSKLASGVPRFSGSGSGNSYSLTISSVEAEDDATYYCQOWSGYPLTFGAGTKLEIK  241
        |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      182  YDTSKVASGVPRFSGSGSGTYSLTISSMEAEDDATYYCQOWSSNPLTFGAGTKLEIK  240

```

RESULT 11
ADV66097

ADV66097 standard; protein; 500 AA.

ADV66097;

24-FEB-2005 (first entry)

Anti-CD3-anti-EpCAM bispecific single chain antibody - SEQ ID 20.

bispecific single chain antibody; epithelial cell adhesion molecule; bispecific CD3; tumor; cancer; cytostatic. EPCAM;

Unidentified.

W02004106383-A1.

09-DEC-2004.

26-MAY-2004; 2004WO-EP005687.

31-MAY-2003; 2003EP-00012133.

1000

(MICR-) MICROMET AG.

Kufer P, Berry M, Offner S, Brischwein K, Wolf A, Raum T; Kohleisen B, Lenkeri-Schuetz U, Baenerle P;

WPI; 2005-021271/02.

New pharmaceutical composition having a bispecific single chain antibody construct, useful for preventing, treating or ameliorating a tumorous disease, such as an epithelial or minimal residual cancer.

Claim 12; SEQ ID NO 20; 227pp; English.

The invention comprises a composition that contains a bispecific single chain antibody consisting of at least two domains, where one of domains binds to human epithelial cell adhesion molecule (EPCAM) antigen, and the second domain binds to human CD3 antigen. The bispecific antibody construct of the invention is useful for the prevention, treatment or amelioration of a tumorous disease, such as an epithelial or minimal residual cancer. The present amino acid sequence represents a bispecific single chain antibody of the invention.

Sequence 500 AA;

Query Match	78.7%;	Score 1004;	DB 9;	length 500;
Best Local Similarity	80.3%;	Pred. No. 5.6e-59;		
Matches 192;	Conservative 17;	Mismatches 30;	Indels 0;	Gaps 0;

```
QY      3 VQLQSGPELEKPGASVKLSCKASGYSFTGYTMNWVKQSHGKSLEWIGLITPYNGASYN 62
      ::||| || :|||::||| |||:|||| :||| ||| | :||
Db      2 IKLQSGAEIARPGASVKMSCKTSGYFTTRYTMHWKQRPQGQLEWIGYINPSRGYTMYN 61
```

```

QY      63 QKFRGKATLTVDKSSSTAYMDLISLTSEDSAVYFCARGGYDGRGPDYWGQGTTVTVSSGV 122
      ||| : ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db      62 QKFKDKATLTITDKSSSTAYMQLSSLTSEDSAVYVCARYDDHYCLDIYWGQGTTLTVSSGG 121
QY      123 GSGSGGGSGGGSDIELTQSPALMSASPGKVTMTCSASSSVSYMHYIQOKSGTSPKRWI 182

```

Db 122 GSSGGGGGGSDIQLTQSPAINASPGKVTMTCRASSSVSYMMWYQOKSGTSPKRWI 181
QY 183 YDTSKIASGVPRFSGSGSGNSYSLTISVEAEDDATYYCCQWSGYPLTFGAGTKLEIK 241
Db 182 YDTSKVASGVPRFSGSGSGTYSLTISMEADDAATYYCCQWSNPLTFGAGTKLEIK 240

RESULT 12

ADV66131
ID ADV66131 standard; protein; 503 AA.
XX
AC ADV66131;
XX
DT 24-FEB-2005 (first entry)
XX
DE Anti-CD3-anti-EpCAM bispecific single chain antibody - SEQ ID 54.
XX
KW bispecific single chain antibody; epithelial cell adhesion molecule;
KW EpCAM; CD3; tumor; cancer; cytostatic.
XX
OS Unidentified.
XX
PN WO2004106383-A1.
XX
PD 09-DEC-2004.
XX
PF 26-MAY-2004; 2004WO-EP005687.
XX
PR 31-MAY-2003; 2003EP-00012133.
PR 31-MAY-2003; 2003EP-00012134.
XX
PA (MICR-) MICROMET AG.
XX
PI Kufer P, Berry M, Offner S, Brieschwein K, Wolf A, Raum T;
PI Kohleisen B, Lenkkeri-Schuetz U, Baeuerle P;
XX
DR WPI; 2005-021271/02.
DR N-PSDB; ADV66130.
XX
PT New pharmaceutical composition having a bispecific single chain antibody
PT construct, useful for preventing, treating or ameliorating a tumorous
PT disease, such as an epithelial or minimal residual cancer.
XX
PS Claim 12; SEQ ID NO 54; 227pp; English.
XX
CC The invention comprises a composition that contains a bispecific single
CC chain antibody consisting of at least two domains, where one of domains
CC binds to human epithelial cell adhesion molecule (EpCAM) antigen, and the
CC second domain binds to human CD3 antigen. The bispecific antibody
CC construct of the invention is useful for the prevention, treatment or
CC amelioration of a tumorous disease, such as an epithelial or minimal
CC residual cancer. The present amino acid sequence represents a bispecific
CC single chain antibody of the invention.
XX
SQ Sequence 503 AA;

Query Match 78.7%; Score 1004; DB 9; Length 503;
Best Local Similarity 80.3%; Pred. No. 5.6e-59;
Matches 192; Conservative 17; Mismatches 30; Indels 0; Gaps 0;
QY 3 VOLQSGPELEKPGASVYKLSCKASGYSTGYTMNWKQSHGKSLWIGLITPYNGASSYN 62
Db 2 IKLQSGAEIARPGASVYKMSCKTSGYTFRTYTMHWKQRPQGLEWIGYINPSRGYTNYN 61
QY 63 QKFRKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGYDGRGFDYWGQGTITVSSSGV 122
Db 62 QKFKDKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGYDGRGFDYWGQGTITVSSSGV 121
QY 123 GSSGGGGGGSDIELTQSPAINASPGKVTMTCSASSSVSYMMWYQOKSGTSPKRWI 182
Db 122 GSSGGGGGGSDIQLTQSPAINASPGKVTMTCRASSSVSYMMWYQOKSGTSPKRWI 181

QY 183 YDTSKIASGVPRFSGSGSGNSYSLTISVEAEDDATYYCCQWSGYPLTFGAGTKLEIK 241
Db 182 YDTSKVASGVPRFSGSGSGTYSLTISMEADDAATYYCCQWSNPLTFGAGTKLEIK 240

RESULT 13

ADV66093
ID ADV66093 standard; protein; 503 AA.
XX
AC ADV66093;
XX
DT 24-FEB-2005 (first entry)
XX
DE Anti-CD3-anti-EpCAM bispecific single chain antibody - SEQ ID 16.
XX
KW bispecific single chain antibody; epithelial cell adhesion molecule;
KW EpCAM; CD3; tumor; cancer; cytostatic.
XX
OS Unidentified.
XX
PN WO2004106383-A1.
XX
PD 09-DEC-2004.
XX
PF 26-MAY-2004; 2004WO-EP005687.
XX
PR 31-MAY-2003; 2003EP-00012133.
PR 31-MAY-2003; 2003EP-00012134.
XX
PA (MICR-) MICROMET AG.
XX
PI Kufer P, Berry M, Offner S, Brieschwein K, Wolf A, Raum T;
PI Kohleisen B, Lenkkeri-Schuetz U, Baeuerle P;
XX
DR WPI; 2005-021271/02.
DR N-PSDB; ADV66092.
XX
PT New pharmaceutical composition having a bispecific single chain antibody
PT construct, useful for preventing, treating or ameliorating a tumorous
PT disease, such as an epithelial or minimal residual cancer.
XX
PS Claim 12; SEQ ID NO 16; 227pp; English.
XX
CC The invention comprises a composition that contains a bispecific single
CC chain antibody consisting of at least two domains, where one of domains
CC binds to human epithelial cell adhesion molecule (EpCAM) antigen, and the
CC second domain binds to human CD3 antigen. The bispecific antibody
CC construct of the invention is useful for the prevention, treatment or
CC amelioration of a tumorous disease, such as an epithelial or minimal
CC residual cancer. The present amino acid sequence represents a bispecific
CC single chain antibody of the invention.
XX
SQ Sequence 503 AA;

Query Match 78.7%; Score 1004; DB 9; Length 503;
Best Local Similarity 80.3%; Pred. No. 5.6e-59;
Matches 192; Conservative 17; Mismatches 30; Indels 0; Gaps 0;
QY 3 VOLQSGPELEKPGASVYKLSCKASGYSTGYTMNWKQSHGKSLWIGLITPYNGASSYN 62
Db 2 IKLQSGAEIARPGASVYKMSCKTSGYTFRTYTMHWKQRPQGLEWIGYINPSRGYTNYN 61
QY 63 QKFRKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGYDGRGFDYWGQGTITVSSSGV 122
Db 62 QKFKDKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGYDGRGFDYWGQGTITVSSSGV 121
QY 123 GSSGGGGGGSDIELTQSPAINASPGKVTMTCSASSSVSYMMWYQOKSGTSPKRWI 182
Db 122 GSSGGGGGGSDIQLTQSPAINASPGKVTMTCRASSSVSYMMWYQOKSGTSPKRWI 181
QY 183 YDTSKIASGVPRFSGSGSGNSYSLTISVEAEDDATYYCCQWSGYPLTFGAGTKLEIK 241
Db 182 YDTSKVASGVPRFSGSGSGTYSLTISMEADDAATYYCCQWSNPLTFGAGTKLEIK 240

RESULT 14

ADV66091

ID ADV66091 standard; protein; 503 AA.

AC ADV66091;

DT 24-FEB-2005 (first entry)

DE Anti-CD3-anti-EpCAM bispecific single chain antibody - SEQ ID 14.

KW bispecific single chain antibody; epithelial cell adhesion molecule;
EpCAM; CD3; tumor; cancer; cytostatic.

OS Unidentified.

PN WO2004106383-A1.

PD 09-DEC-2004.

PF 26-MAY-2004; 2004WO-EP005687.

PR 31-MAY-2003; 2003EP-00012133.

PR 31-MAY-2003; 2003EP-00012134.

PA (MICR-) MICROMET AG.

PI Kufer P, Berry M, Offner S, Brischwein K, Wolf A, Raum T;
PI Kohleisen B, Lenkeri-Schuetz U, Baenerle P;

DR WPI; 2005-021271/02.

DR N-PSDB; ADV66090.

PT New pharmaceutical composition having a bispecific single chain antibody
PT construct, useful for preventing, treating or ameliorating a tumorous
PT disease, such as an epithelial or minimal residual cancer.

PS Claim 12; SEQ ID NO 14; 227pp; English.

CC The invention comprises a composition that contains a bispecific single
CC chain antibody consisting of at least two domains, where one of domains
CC binds to human epithelial cell adhesion molecule (EpCAM) antigen, and the
CC second domain binds to human CD3 antigen. The bispecific antibody
CC construct of the invention is useful for the prevention, treatment or
CC amelioration of a tumorous disease, such as an epithelial or minimal
CC residual cancer. The present amino acid sequence represents a bispecific
CC single chain antibody of the invention.

SQ Sequence 503 AA;

Query Match 78.7%; Score 1004; DB 9; Length 503;

Best Local Similarity 80.3%; Pred. No. 5.6e-59;

Matches 192; Conservative 17; Mismatches 30; Indels 0; Gaps 0;

QY 3 VOLQSGPELEKPGASVKSCKASGYFTGYTMNVKQSHGKSLWIGLITPYNGASSYN 62

DB 2 IKLQQSGAEIARPGASVKSCKTSGYTFRTYTMHWKQRPQGLEWIGYNPSRGYTNYN 61

QY 63 QKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVVFCARGGYDGRGFDYWGQTTVTSSGV 122

DB 62 QKFKDKATLTITDKSSSTAYMDLLSLTSEDSAVVYCCARYDDHYCLDYWGQTTTLTVSSGG 121

QY 123 GSGGGGGGGGGSDIELTQSPAIMSASPGKVTMTCSASSSVSYMHVYQOKSGTSPKRWI 182

DB 122 GSGGGGGGGGGSDIQLTQSPAIMSASPGKVTMTCRASSSVSYMHVYQOKSGTSPKRWI 181

QY 183 YDTSKLASGVPRFSGSGSNSYSLTISVEAEDATYYCQOWSGYPLTFGAGTKLEIK 241

DB 182 YDTSKVASGVPRFSGSGSGTYSYLTISMEADATYYCQOWSSNPLTFGAGTKLEIK 240

RESULT 15

ADV14540

ID ADV14540 standard; protein; 503 AA.

AC ADV14540;

DT 24-FEB-2005 (first entry)

DE Bispecific VH(CD3)-VL(CD3)-VH(CD19) antibody protein Seq 14.

KW bispecific antibody; antibody engineering; antibody therapy; CD3; CD19;
KW proliferative disorders; cancer; tumor; B-cell leukemia; inflammation;
KW immune disorder; autoimmune disease; rheumatoid arthritis;
KW viral infection; allergy; parasitic infection; graft-versus-host disease;
KW cytostatic; antiinflammatory; immunosuppressive; antimicrobial-gen.;
KW antirheumatic; antiarthritic; virucide; antiparasitic; antiallergic.

OS Homo sapiens.
OS Synthetic.

PN WO2004106381-A1.

PD 09-DEC-2004.

PF 26-MAY-2004; 2004WO-EP005685.

PR 31-MAY-2003; 2003EP-00012136.

PA (MICR-) MICROMET AG.

PI Kufer P, Lutterbuese R, Kohleisen B, Zeman S, Baenerle P;

DR WPI; 2005-021270/02.

DR N-PSDB; ADV14539.

PT Use of bispecific single chain antibody construct, nucleic acid sequence
PT encoding the antibody construct, vector containing the nucleic acid or
PT host transformed with the vector for the treatment of e.g. proliferative
PT and autoimmune disease.

PS Claim 9; SEQ ID NO 14; 115pp; English.

CC This invention relates to novel pharmaceutical compositions that comprise
CC a bispecific single chain antibody construct, a nucleic acid sequence
CC encoding the antibody construct and a vector that contains the nucleic
CC acid sequence. Specifically, it refers to an antibody construct that
CC contains binding domains specific for the human T cell differentiation
CC antigens CD3 and CD19, with specific variable heavy and light chain
CC regions. In particular such constructs include, from the N- to C-termini,
CC in the order, VH(CD19)-VL(CD19)-VH(CD3)-VL(CD3)-VH(CD3)-VL(CD19)
CC -VL(CD19), or VH(CD3)-VL(CD3)-VL(CD19)-VH(CD19). The present invention
CC describes a method of culturing the host transformed with this vector in
CC order to recover expressed bispecific single chain antibodies from the
CC culture solution. Note that the pharmaceutical composition additionally
CC comprises a proteinaceous compound that provides an activation signal for
CC immune effector cells. Furthermore, this invention provides compositions
CC that can be used for the treatment, prevention or amelioration of
CC proliferative disease, minimal residual cancer, tumorous disease (e.g. B-
CC cell leukemia), inflammatory disease, immunological disorder, autoimmune
CC disease (e.g. rheumatoid arthritis), infectious disease, viral disease,
CC allergic reactions, parasitic reactions, graft-versus-host diseases, host
CC -versus-graft diseases and B-cell malignancies. As such, these
CC compositions exhibit cytostatic, antiinflammatory, immunosuppressive,
CC antimicrobial, antirheumatic, antiarthritic, virucide, antiparasitic and
CC antiallergic activities. In addition, these compositions provide well-
CC tolerated and convenient medicaments that are highly active and potent at
CC low concentrations and as such avoid adverse side effects including
CC hypersensitivity and inflammatory events caused by excessive protein
CC concentrations. This polypeptide sequence is a bispecific single chain
CC antibody protein that targets human CD3 and CD19 antigens, as given in an
CC exemplification of the invention.

SQ Sequence 503 AA;

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: April 3, 2006, 05:30:32 ; Search time 61 Seconds
(without alignments)
1650.768 Million cell updates/sec

Title: US-09-979-539-1

Perfect score: 1276
Sequence: 1 MQVQLQQSGPELEKPGASVK.....CQWMSGYPLTFGAGTKLEIK 241

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 segs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications_AA_Main:*
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep:*
2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep:*
3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep:*
4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep:*
5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep:*
6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1274	99.8	241	US-10-973-718-5	Sequence 5, Appli
2	1025.5	80.4	242	US-10-259-087A-20	Sequence 20, Appli
3	1025.5	80.4	242	US-10-689-006-20	Sequence 20, Appli
4	1010.5	79.2	239	US-09-808-037-6	Sequence 6, Appli
5	1010.5	79.2	239	US-10-162-889-6	Sequence 6, Appli
6	1010.5	79.2	239	US-10-384-788-6	Sequence 6, Appli
7	1010.5	79.2	239	US-10-618-856-6	Sequence 6, Appli
8	1010.5	79.2	239	US-10-749-522-6	Sequence 6, Appli
9	1010.5	79.2	239	US-11-073-526-6	Sequence 6, Appli
10	1003	78.6	261	US-10-689-006-24	Sequence 24, Appli
11	989.5	77.5	242	US-10-259-087A-18	Sequence 18, Appli
12	989.5	77.5	242	US-10-689-006-18	Sequence 18, Appli
13	967.5	75.8	492	US-10-682-845-63	Sequence 63, Appli
14	967.5	75.8	492	US-10-682-845-79	Sequence 79, Appli
15	967.5	75.8	492	US-10-682-845-83	Sequence 83, Appli
16	966.5	75.7	492	US-10-682-845-87	Sequence 87, Appli
17	966	75.7	246	US-10-861-617-15	Sequence 15, Appli
18	965.5	75.7	492	US-10-682-845-61	Sequence 61, Appli
19	965.5	75.7	492	US-10-682-845-71	Sequence 71, Appli
20	965.5	75.7	492	US-10-682-845-73	Sequence 73, Appli
21	965.5	75.7	492	US-10-682-845-77	Sequence 77, Appli
22	964.5	75.6	243	US-10-966-406-2	Sequence 2, Appli
23	964.5	75.6	409	US-10-362-591-2	Sequence 2, Appli
24	964.5	75.6	492	US-10-682-845-59	Sequence 59, Appli
25	964.5	75.6	492	US-10-682-845-67	Sequence 67, Appli
26	964.5	75.6	492	US-10-682-845-69	Sequence 69, Appli
27	964.5	75.6	499	US-10-805-177-111	Sequence 111, App

28	964.5	75.6	500	4	US-10-168-809-22	Sequence 22, Appli
29	963.5	75.5	492	4	US-10-682-845-75	Sequence 75, Appli
30	963.5	75.5	492	4	US-10-682-845-85	Sequence 85, Appli
31	962.5	75.4	260	4	US-10-435-614-20	Sequence 20, Appli
32	961	75.3	246	5	US-10-861-617-17	Sequence 17, Appli
33	961	75.3	657	5	US-10-723-003-48	Sequence 48, Appli
34	961	75.3	657	6	US-11-004-639-48	Sequence 48, Appli
35	960.5	75.3	492	4	US-10-682-845-65	Sequence 65, Appli
36	959.5	75.2	256	4	US-10-247-488-2	Sequence 2, Appli
37	959.5	75.2	258	4	US-10-247-488-4	Sequence 4, Appli
38	957.5	75.0	492	4	US-10-682-845-81	Sequence 81, Appli
39	956.5	75.0	495	3	US-09-948-004-18	Sequence 18, Appli
40	956.5	75.0	495	5	US-10-672-932-18	Sequence 18, Appli
41	956	74.9	281	4	US-10-112-788-9	Sequence 9, Appli
42	956	74.9	281	4	US-10-435-614-15	Sequence 15, Appli
43	950	74.5	438	4	US-10-244-821-88	Sequence 88, Appli
44	948.5	74.3	260	4	US-10-435-614-19	Sequence 19, Appli
45	941.5	73.8	423	4	US/10/013	Sequence 8, Appli

ALIGNMENTS

RESULT 1
US-10-973-718-5
Sequence 5, Application US/10973718
Publication No. US20050214304A1
GENERAL INFORMATION:
APPLICANT: Pastan, Ira H.
APPLICANT: Chowdhury, Partha S.
APPLICANT: The Government of the United States
APPLICANT: as represented by The Secretary of the
APPLICANT: Department of Health and Human Services
TITLE OF INVENTION: Antibodies, Including Fv Molecules, and
TITLE OF INVENTION: Immunocjugates Having High Binding Affinity for
TITLE OF INVENTION: Mesothelin and Methods for Their Use
FILE REFERENCE: 015280-339100US
CURRENT APPLICATION NUMBER: US/10/973, 718
CURRENT FILING DATE: 2004-10-25
PRIOR APPLICATION NUMBER: US/09/581, 345
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: US 60/067, 175
PRIOR FILING DATE: 1997-12-01
PRIOR APPLICATION NUMBER: WO PCT/US98/25270
NUMBER OF SEQ ID NOS: 9
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 5
LENGTH: 241
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURES:
OTHER INFORMATION: Description of Artificial Sequence:SS scFv
US-10-973-718-5
Query Match 99.8%; Score 1274; DB 5; Length 241;
Best Local Similarity 99.6%; Pred. No. 1.2e-82;
Matches 240; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 MQVQLQQSGPELEKPGASVKLSCKASGYSFTGYTMWVKQSHGKSIEMWIGLITPYNGASS 60
Db 1 MQVQLQQSGPELEKPGASVKISCKASGYSFTGYTMWVKQSHGKSIEMWIGLITPYNGASS 60
QY 61 YNOKFRGKATLTVDKSSSTAYMDLISLTSEDSAYVFCARGGYDGRGFDYWGQGTIVVSS 120
Db 61 YNOKFRGKATLTVDKSSSTAYMDLISLTSEDSAYVFCARGGYDGRGFDYWGQGTIVVSS 120
QY 121 GVGSGGGGGGGGGSDIELTQSPAIMSASPGKVTMTCSASSSVSYMHMYQOKSGTSPKR 180
Db 121 GVGSGGGGGGGGGSDIELTQSPAIMSASPGKVTMTCSASSSVSYMHMYQOKSGTSPKR 180
QY 181 WIYDTSKLASGVVGRFSGSGGNSYSLTISVVEADDATYCCQWMSGYPLTFGAGTKLEI 240
Db 181 WIYDTSKLASGVVGRFSGSGGNSYSLTISVVEADDATYCCQWMSGYPLTFGAGTKLEI 240

Db 181 WIYDTSKLASGVPRFSGSGSGNSYSLLTSSVEAEDDATYYCQQWSGYPLTFGAGTKLEI 240
QY 241 K 241
Db 241 K 241

RESULT 2

US-10-259-087A-20
; Sequence 20, Application US/10259087A
; Publication No. US20030130190A1
; GENERAL INFORMATION:
; APPLICANT: Vanderbilt University
; APPLICANT: Hallahan, Dennis E
; APPLICANT: Qu, Shmian
; TITLE OF INVENTION: IN VIVO PANNING FOR LIGANDS TO RADIATION-INDUCED MOLECULES
; FILE REFERENCE: 1242/47/2
; CURRENT APPLICATION NUMBER: US/10/259,087A
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: US 60/328123
; PRIOR FILING DATE: 2001-10-03
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 20
; LENGTH: 242
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificial antibody ligand number 2
US-10-259-087A-20

Query Match 80.4%; Score 1025.5; DB 4; Length 242;
Best Local Similarity 81.7%; Pred. No. 5.2e-65;
Matches 196; Conservative 13; Mismatches 30; Indels 1; Gaps 1;

QY 2 QVQLQSGPELEKPGASVSKLSCKASGYSTGYTMNWVKQSHGKSLIEWIGLITPYNGASSY 61
Db 3 QVQLQSGPELVKPGASVSKMSCKASGYTFTSYVMHWKQKPGQGLEWIGYINPYNDGTRY 62
QY 62 NQKFRGKATLTVDKSSSTAYMDLSTSEDSAVYFCARGYDGRGFDYWGQGTITVSSG 121
Db 63 NEKFKGKALITSDKSSSTAYMELSLTSEDSAVYFCARFNGY-ALDYWGQGTITVSSG 121
QY 122 VGGSGGGSGGSDIELTQSPAIMSASPGKYTMTCSASSSVSYMHYQOKSGTSPKRW 181
Db 122 GGGSGGGSGGSDIELTQSPTIMSASPGKYTITCSASSSVSYMHWFQOKPGTSPKRW 181
QY 182 IYDTSKLASGVPRFSGSGSGNSYSLLTSSVEAEDDATYYCQQWSGYPLTFGAGTKLEIK 241
Db 182 IYGTSLNLSAGVPRFSGSGSGTSTSLTSSMEADATYYCQQWSYPLTFGGGTGLEIK 241

RESULT 3

US-10-689-006-20
; Sequence 20, Application US/10689006
; Publication No. US20040191249A1
; GENERAL INFORMATION:
; APPLICANT: Vanderbilt University
; APPLICANT: Hallahan, Dennis E
; APPLICANT: Mernaugh, Raymond
; TITLE OF INVENTION: PHAGE ANTIBODIES TO RADIATION-INDUCIBLE NEOANTIGENS
; FILE REFERENCE: 1242/72
; CURRENT APPLICATION NUMBER: US/10/689,006
; CURRENT FILING DATE: 2003-10-20
; PRIOR APPLICATION NUMBER: US 09/914,605
; PRIOR FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: US 10/259,087
; PRIOR FILING DATE: 2002-09-27
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 242
; TYPE: PRT

; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Artificial antibody ligand number 2
US-10-689-006-20

Query Match 80.4%; Score 1025.5; DB 4; Length 242;
Best Local Similarity 81.7%; Pred. No. 5.2e-65;
Matches 196; Conservative 13; Mismatches 30; Indels 1; Gaps 1;

QY 2 QVQLQSGPELEKPGASVSKLSCKASGYSTGYTMNWVKQSHGKSLIEWIGLITPYNGASSY 61
Db 3 QVQLQSGPELVKPGASVSKMSCKASGYTFTSYVMHWKQKPGQGLEWIGYINPYNDGTRY 62
QY 62 NQKFRGKATLTVDKSSSTAYMDLSTSEDSAVYFCARGYDGRGFDYWGQGTITVSSG 121
Db 63 NEKFKGKALITSDKSSSTAYMELSLTSEDSAVYFCARFNGY-ALDYWGQGTITVSSG 121
QY 122 VGGSGGGSGGSDIELTQSPAIMSASPGKYTMTCSASSSVSYMHYQOKSGTSPKRW 181
Db 122 GGGSGGGSGGSDIELTQSPTIMSASPGKYTITCSASSSVSYMHWFQOKPGTSPKRW 181
QY 182 IYDTSKLASGVPRFSGSGSGNSYSLLTSSVEAEDDATYYCQQWSGYPLTFGAGTKLEIK 241
Db 182 IYGTSLNLSAGVPRFSGSGSGTSTSLTSSMEADATYYCQQWSYPLTFGGGTGLEIK 241

RESULT 4

US-09-808-037-6
; Sequence 6, Application US/09808037
; Patent No. US20020052311A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: HANAN, Elia
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT AND/OR DIAGNOSIS OF
; TITLE OF INVENTION: NEUROLOGICAL DISEASES AND DISORDERS
; FILE REFERENCE: SOLOMON-2D
; CURRENT APPLICATION NUMBER: US/09/808,037
; CURRENT FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: 09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6
; LENGTH: 239
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-808-037-6

Query Match 79.2%; Score 1010.5; DB 3; Length 239;
Best Local Similarity 79.8%; Pred. No. 6e-64;
Matches 194; Conservative 16; Mismatches 26; Indels 7; Gaps 2;

QY 2 QVQLQSGPELEKPGASVSKLSCKASGYSTGYTMNWVKQSHGKSLIEWIGLITPYNGASSY 61
Db 1 QVQLQSGPELVKPGASVSKMSCKASGYTFTSYVMHWKQKPGQGLEWIGYINPYNDGTRY 60
QY 62 NQKFRGKATLTVDKSSSTAYMDLSTSEDSAVYFCARG--GYDGRGFDYWGQGTITV 118
Db 61 NQKFRGKATLTVDKSSSTAYMELARLTSEDSALYYCARGATMSY----FDYWGQVTITV 116
QY 119 SSGVGGSGGGSGGSDIELTQSPAIMSASPGKYTMTCSASSSVSYMHYQOKSGTSP 178
Db 117 SSGGSGGGSGGSDIELTQSPAIMSASPGKYTMTCSASSSVSYMHYQOKSGTSP 176
QY 179 KRWTYDTSKLASGVPRFSGSGSGNSYSLLTSSVEAEDDATYYCQQWSGYPLTFGAGTKL 238
Db 177 KRWTYDTSKLASGVPRFSGSGSGTSTSLTSSMEADATYYCHGRSSYPFTFGGAKL 236
QY 239 EIK 241


```
QY 62 NOKFRKATLTVDKSSSTAYMDLILTSSEDSAVYFCARG---GYDGRGFDYWGQTTVTV 118
|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 61 NOKFKGKATMTVDKSSSTAYMELARLTSEDSALYYCARGATMSY----FDYWGQTTVTV 116
QY 119 SSGVGSGGGGGGGGGSDIELTQSPAIMSASPEKVTMTCSASSSVSYMHYQOKSGTSP 178
|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 117 SSGGGGGGGGGGGGGSDIELTQSPAIMSASPEKVTMTCSASSSISYMHYQOKPGTSP 176
QY 179 KRWIYDTSKLASGVPRFSGSGSGNSYSLTSSVEAEDDATYYCCQWNGYPLTFGAGTKL 238
||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 177 KRWIYDTSKLASGVPARFSGSGSGTSTSLTSSMEADATYYCHQRSSYPFTFGGAKL 236
QY 239 EIK 241
|||
Db 237 EIK 239

RESULT 8
US-10-749-522-6
; Sequence 6, Application US/10749522
; Publication No. US20050089510A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: HANAN, Bilat
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME USEFUL IN DIAG
; FILE REFERENCE: SOLOMON=2B
; CURRENT APPLICATION NUMBER: US/10/749,522
; CURRENT FILING DATE: 2004-01-02
; PRIOR APPLICATION NUMBER: US/09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: Patentln version 3.0
; SEQ ID NO 6
; LENGTH: 239
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-749-522-6

Query Match 79.2%; Score 1010.5; DB 5; Length 239;
Best Local Similarity 79.8%; Pred. No. 6e-64;
Matches 194; Conservative 16; Mismatches 26; Indels 7; Gaps 2;

QY 2 QVQLQSGPELEKPGASVKLSCKASGYFTGYTMNWVKQSHGKSLEWIGLITPYNGASSY 61
|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 1 QVKLQESGAELVPRGVSVKISCKSGYFTFDYAMHWVKQSHAKSLEWIGVISTYYGDASY 60
QY 62 NOKFRKATLTVDKSSSTAYMDLILTSSEDSAVYFCARG---GYDGRGFDYWGQTTVTV 118
|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 61 NOKFKGKATMTVDKSSSTAYMELARLTSEDSALYYCARGATMSY----FDYWGQTTVTV 116
QY 119 SSGVGSGGGGGGGGGGGSDIELTQSPAIMSASPEKVTMTCSASSSVSYMHYQOKSGTSP 178
|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 117 SSGGGGGGGGGGGGGGGSDIELTQSPAIMSASPEKVTMTCSASSSISYMHYQOKPGTSP 176
QY 179 KRWIYDTSKLASGVPRFSGSGSGNSYSLTSSVEAEDDATYYCCQWNGYPLTFGAGTKL 238
||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 177 KRWIYDTSKLASGVPARFSGSGSGTSTSLTSSMEADATYYCHQRSSYPFTFGGAKL 236
QY 239 EIK 241
|||
Db 237 EIK 239

RESULT 9
US-11-073-526-6
; Sequence 6, Application US/11073526
; Publication No. US20050152878A1

; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: FRENKEL, Dan
; APPLICANT: HANAN, Bilat
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME USEFUL IN DIA
; FILE REFERENCE: SOLOMON=2C
; CURRENT APPLICATION NUMBER: US/11/073,526
; CURRENT FILING DATE: 2005-03-08
; PRIOR APPLICATION NUMBER: US/09/830,954
; PRIOR FILING DATE: 2001-08-07
; PRIOR APPLICATION NUMBER: PCT/IL00/00518
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: Patentln version 3.1
; SEQ ID NO 6
; LENGTH: 239
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-073-526-6

Query Match 79.2%; Score 1010.5; DB 6; Length 239;
Best Local Similarity 79.8%; Pred. No. 6e-64;
Matches 194; Conservative 16; Mismatches 26; Indels 7; Gaps 2;

QY 2 QVQLQSGPELEKPGASVKLSCKASGYFTGYTMNWVKQSHGKSLEWIGLITPYNGASSY 61
|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 1 QVKLQESGAELVPRGVSVKISCKSGYFTFDYAMHWVKQSHAKSLEWIGVISTYYGDASY 60
QY 62 NOKFRKATLTVDKSSSTAYMDLILTSSEDSAVYFCARG---GYDGRGFDYWGQTTVTV 118
|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 61 NOKFKGKATMTVDKSSSTAYMELARLTSEDSALYYCARGATMSY----FDYWGQTTVTV 116
QY 119 SSGVGSGGGGGGGGGGGSDIELTQSPAIMSASPEKVTMTCSASSSVSYMHYQOKSGTSP 178
|||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 117 SSGGGGGGGGGGGGGGGSDIELTQSPAIMSASPEKVTMTCSASSSISYMHYQOKPGTSP 176
QY 179 KRWIYDTSKLASGVPRFSGSGSGNSYSLTSSVEAEDDATYYCCQWNGYPLTFGAGTKL 238
||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 177 KRWIYDTSKLASGVPARFSGSGSGTSTSLTSSMEADATYYCHQRSSYPFTFGGAKL 236
QY 239 EIK 241
|||
Db 237 EIK 239

RESULT 10
US-10-689-006-24
; Sequence 24, Application US/10689006
; Publication No. US20040191249A1
; GENERAL INFORMATION:
; APPLICANT: Vanderbilt University
; APPLICANT: Hallahan, Dennis E
; APPLICANT: Mernaugh, Raymond
; TITLE OF INVENTION: PHAGE ANTIBODIES TO RADIATION-INDUCIBLE NEOANTIGENS
; FILE REFERENCE: 1242/72
; CURRENT APPLICATION NUMBER: US/10/689,006
; CURRENT FILING DATE: 2003-10-20
; PRIOR APPLICATION NUMBER: US 09/914,605
; PRIOR FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: US 10/259,087
; PRIOR FILING DATE: 2002-09-27
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: Patentln version 3.2
; SEQ ID NO 24
; LENGTH: 261
; TYPE: PRT
```



```

; ORGANISM: artificial
;
; FEATURE:
; OTHER INFORMATION: nucleic acid encoding scFv antibody 10A
US-10-689-006-24

```

Query Match	78.6%;	Score 1003;	DB 4;	Length 261;
Best Local Similarity	80.9%;	Pred. No. 2.2e-63;		
Matches 195;	Conservative 17;	Mismatches 27;	Indels 2;	Gaps 2;

```
QY      2 QVQLQQSGPELEKPGASVKLSCKASGYSTFGITMNMWVKQHGSKEIWLIGLTIPYNGASSY 61
       ||::|||:::||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||
Db      3 QVTLQQSGPELVKPGASVKMSCKASGTYFTSYVMHWVKQSNGSKSEIWIGTIDPYGGTSY   62
```

```

QY      62  NQKRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCAR-CGYDGRGFDYWGQTTVTYSS  120
      |||:|||||:||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db      63  NQKRGKATLTVDKSSSTAYIQLKSLTSEDSAVYFCARMDGYG-GFSTWGQGMTVTYSS  121

```

QY 121 GVGSGGGGSGGGSDIELTQSPAIMSASPEKVTMTCSASSVSVMHWYQOKSGTSPKR 180
| | | | | : | | | : | | : | | | |
Db 122 GGGSGGGGSGGGSDIELTQSPAIMSATLGEKVTMSCRASSNVKMYWYQOKSGASPKL 181

```
OY      181 WIYDTSKLASGVPRFRFGSGS GSNYSYLTISSVEAEADATYYCQOWSGYPETFGAGTKLEI   240  
        ||| ||||| ||||| ||||| ||||| : | : |||||  
Db     182 WITYTSLNLAGVPRFSGSGSGSTSYLTISSVEAEADATYYCCQFTTSRYTFGSGTKLEI   241
```

Qy	241	K	241
Db	242	K	242

RESULT 11
US-10-259-087A-18

```

; Sequence 18 Application US/10259087A
; Publication No. US20030130190A1
;
; GENERAL INFORMATION:
; APPLICANT: Vanderbilt University
; APPLICANT: Hallahan, Dennis E
; APPLICANT: Qu, Shimian
; TITLE OF INVENTION: IN VIVO PANNING FOR LIGANDS TO RADIATION-INDUCED MOLECULES
; FILE REFERENCE: 1242/47/2
;

```

```

: CURRENT APPLICATION NUMBER: US/10/259, 087A
:
: CURRENT FILING DATE: 2002-09-27
:
: PRIOR APPLICATION NUMBER: US 60/328123
:
: PRIOR FILING DATE: 2001-10-03
:
: NUMBER OF SEQ ID NOS: 20
:
: SOFTWARE: PatentIn version 3.1
:
: SEQ ID NO 18
:
: LENGTH: 242
:

```

```

; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificial antibody ligand number 1
US-10-259-087A-18

```

Query Match	77.5%;	Score 989.5;	DB 4;	Length 242;
Best Local Similarity	80.4%;	Pred. No. 1.9e-62;		
Matches 193; Conservative	14;	Mismatches 32;	Indels 1;	Gaps 1;

```
Qy      2 QVQLQQSGPELEKPGASVKLSCKASGYSFTGTMMNWVKOSHKSLEWIGLTIPYNGASSY 61
        ||::|||:|||::|||::|||::|||::|||::|||::|||::|||::|||::|||
Db      3 QVQLQQSGAEIYMPGASVKMSCKASGYTFDTMMHWKQRPGGLEWIGALDTSDSYSTS 62
```

```
QY 62 NQKFRGATLTVDKSSSTAYMDLSLTSSEDSAVYFCARGGYDGRGFDYWGQCTTVTVSSG 121
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
DB 63 NQKFKGATLTVDESSSTAYMQLSLTSSEDSAVYFCARGGYG-AFDYWGQCTTVTVSSG 121
```

```
Qy      122 VGGSGGGSGGGSDIELTQS PAIMAS PGEKVTMTCSASSSVYMHWYOQKSGTSPKRW 181
        |||||
Db      122 GGGSGGGSGGGSDIELTQS PTMMA SPGEKVITTCRASSSVYMHWFOQKSGTSPKPW 181
```

```
Oy      182 IYDTSKASGVPGRFSGSGS GNSYLTISSVEAEDATYYCCQWSGYPLTFGAGTKLEIK 241
         |||||          :|||||
Db      182 IYDTSKASGVPPDRFSGSGSGT SYSLTISSMEAEADATYYCLGRSSPYTFAGGKTLEIK 241
```

RESULT 12
US-10-689-006-18

Sequence 18, Application US/10689006
Publication No. US20040191249A1

```

; GENERAL INFORMATION:
; APPLICANT: Vanderbilt University

```

APPLICANT: Hallahan, Dennis E
APPLICANT: Mernaugh, Raymond

;; TITLE OF INVENTION: PHAGE ANTIBODIES TO RADIATION-INDUCIBLE NEOANTIGENS
; FILE REFERENCE: 1242/72
;

```

; CURRENT APPLICATION NUMBER: US/10/689,006
; CURRENT FILING DATE: 2003-10-20

```

;
PRIOR APPLICATION NUMBER: US 09/914,603
;
PRIOR FILING DATE: 2001-08-30
;

;
PRIOR APPLICATION NUMBER: US 10/259,087
;
PRIOR FILING DATE: 2002-09-27
;

```

; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2.2

```

```

; SEQ ID NO 18
; LENGTH: 24

```

```

; TYPE: PRT
; ORGANISM: Artificial

```

OTHER INFORMATION: Artificial antibody ligand number 1
US-10-689-006-18

Query Match	77.5%;	Score 989.5;	DB 4;	Length 242;
Best Local Similarity	80.4%;	Pred. No. 1.9e-62;		
Matches 193; Conservative	14;	Mismatches 32;	Indels 1;	Gaps 1;

```

Qy      2 QVQLQQSGEPELEKPGASVYKLSCKASGYSTGYTMNWVKQSHGKSLIEWIGLTIPYNGASSY 61
      ||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      3 QVQLQQSGAEIVMPGASVYMSCKASGYTFTDYMHWVQKRPQGLEWIGALDTSDSYTSY 62

```

QY 62 NQKFRGATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDYWGQITTVVSSG 121
| | | : | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 63 NQKFKGATLTVDESSSTAYMQLSLTSEDSAVYCARGGYS - AFDYWGGITTVVSSG 121

```
QY      122 VGGSGGGGSGGGSDIELTQSPTMAASPGKEKVTMTCSASSSVSYMHWFQQXSGTSPKRW 181Y
       |||||
DB      122 GGGSGGGGSGGGSDIELTQSPTMAASPGKEKVTITCRASSSVSYMHWFQQXSGTSPKPW 181Y
```

```
Qy      182 IYDTSKLASGVPGRRPSGSGSGNISLTIISSVEAEADATYYCQOWSGYPPLTFAGAKTLEIK 241
        |||||
Db      182 IYDTSKLASGVPRFRSGSGSGSTSYSLTISSMEAEADATYYCLQRSSYPPTFGAKTLEIK 241
```

RESULT 13
US-10-682-845-63

; Sequence 63, Application US/10682845
; Publication No. US20040162411A1

;; GENERAL INFORMATION:
; APPLICANT: Lanzavecchia, Antonio

;; TITLE OF INVENTION: Potent T cell modulating molecules
;; FILE REFERENCE: G2296 US

```

; CURRENT APPLICATION NUMBER: US/10/682,845
; CURRENT FILING DATE: 2003-10-10

```

;
; PRIOR APPLICATION NUMBER: US 60/419,149
; PRIOR FILING DATE: 2002-10-18
;

;
; PRIOR APPLICATION NUMBER: CA 2,403,313
;
; PRIOR FILING DATE: 2002-10-11
;

```

; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: PatentIn version 3.1

```

```

; SEQ ID NO 63
; LENGTH: 492

```

```

; TYPE: PRT
; ORGANISM: artificial sequence

```

```

; FEATURE: scFv EPCAMxCD3 with M4 mutant in anti-CD3 part
; OTHER INFORMATION:

```

US-10-682-845-63

	Query Match	75.8%;	Score 967.5;	DB 4;	Length 492;
	Best Local Similarity	77.3%;	Pred. No. 1.4e-60;		
	Matches 187;	Conservative 17;	Mismatches 35;	Indels 3;	Gaps 1
QY	3 VQLQQSGPELEKPGASVKLSCKASGYSTGYTMNWKQSHGKSLEWIGLITPYNGASSYN	62			
Db	245 IKLQQSGAEIARPGASVKKMSCKTSGITFTRYTMHWKPDPGGGLEWIGYINPSRGTYNN	304			
QY	63 QKRKGATLTVDKSSSTAYMDLLSLTSEDSAVFECARGGDGRGFYWGGTTYVSS--	120			
Db	305 QKFSDKATLTDDKSSSTAYMQLSSLTSSEDSAVVYCARYSDHYCLDYGQGTTLVSSVE	364			
QY	121 -GVGGSGGGSGGGSGDIELTQSPAIMSAPGEKYMTCSASSSVSMHMYOQKSGTSPK	179			
Db	365 GGGSGSGSGSGSGGVDDIQLTQSPAIMSASPGEKYMTCRASSSVSYMMNYOQKSGTSPK	424			
QY	180 RNIYDTSKLASGVPRFSGSGGSNSYLTISSVEAEDDATYYCCQWSGYPLTFGAGTKLE	239			
Db	425 RNLYDTSKVASGVPIRFSGSGGSTYSLTISSMEAEADATYYCQCQWSNPPLTFGAGTKLE	484			
QY	240 IK 241 :				
Db	485 LK 486 :				

```

RESULT 14
US-10-682-845-79
; Sequence 79, Application US/10682845
; Publication No. US20040162411A1
; GENERAL INFORMATION:
; APPLICANT: Lanzavecchia, Antonio
; TITLE OF INVENTION: Potent T cell modulating molecules
; FILE REFERENCE: G2296 US
; CURRENT APPLICATION NUMBER: US/10/682,845
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: US 60/419,149
; PRIOR FILING DATE: 2002-10-18
; PRIOR APPLICATION NUMBER: CA 2,403,313
; PRIOR FILING DATE: 2002-10-11
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 79
; LENGTH: 492
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: scFv EpcAMxCD3 with M31 mutant in anti-CD3 part
US-10-682-845-79

```

Query Match	75.8%;	Score 967.5;	DB 4;	Length 492;
Best Local Similarity	77.8%;	Pred. No. 1.4e-60;		
Matches 189;	Conservative 18;	Mismatches 31;	Indels 5;	Gaps 3;

QY	3	VOLQSGPELEKPGASVYLSCSKASGYSTGYTMNVKQSHGSLWEILITPRNGASTN	62
Dd	245	IKLQSGAEIARPGASVCMSCXTSGYTFRYTMHVQRPGGLEWIGTINPSRGYTNN	304
QY	63	QKFRKATLTVDKSSSTAAMDLSLTSEDSAVVFPCARGCYDGR-GFDYWGQTTVTVS-	120
Dd	305	QKFQDKATLTTDKSSSTAYMQLSSLTSEDSAVVYCAR-YEGRYCLDYMGQTTLTTSV	363
QY	121	--GVGSGGGGGSGGGSDIELTQSPAIMASAPGEKVMTMCASSSVSYMHVYOQKSGETSP	178
Dd	364	EGSGSGSGSGSGSGVDIDILTQSPAIMASAPGEKVMTMCRASSSVSYMMVYOQKSGETSP	423
QY	179	KRWIYDTSKLASGVPGRFSGSGSGNSYSLLTISSVEAEDDATYYCQOWSGYPLTFGAGTKL	238
Dd	424	KRWIYDTSKVASGVPYRFSGSGSGTYSYLLTISSMEAEDDATYYCQOWSSNPPLTFGAGTKL	483
QY	239	EIK 241	
Dd	484	ELK 486	

```

RESULT 15
US-10-682-845-83
; Sequence 83, Application US/10682845
; Publication No. US20040162411A1
GENERAL INFORMATION:
; APPLICANT: Lanzavecchia, Antonio
; TITLE OF INVENTION: Potent T cell modulating molecules
; FILE REFERENCE: G2296 US
; CURRENT APPLICATION NUMBER: US/10/682,845
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: US 60/419,149
; PRIOR FILING DATE: 2002-10-18
; PRIOR APPLICATION NUMBER: CA 2,403,313
; PRIOR FILING DATE: 2002-10-11
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 83
; LENGTH: 492
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: scFv EPCAMxCD3 with M65 mutant in anti-CD3 part
US-10-682-845-83

```

[illegible]

Search completed: April 3, 2006, 05:33:08
Job time : 62 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioacceleration Ltd.

OM protein - protein search, using sw model

Run on: April 3, 2006, 05:30:32 ; Search time 45 Seconds
(without alignments)
163.033 Million cell updates/sec

Title: US-09-979-539-1

Perfect score: 1276

Sequence: 1 MQVQLQSGPELEKPGASVK.....CQQWSGYPLTFGAGTKLEIK 241

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 180808 seqs, 30441898 residues

Total number of hits satisfying chosen parameters: 180808

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- 1: Published Applications_AA_New:*
- 2: /SIDS5/ptodata/1/pubpaa/US08_NEW_PUB.pep:*
- 3: /SIDS5/ptodata/1/pubpaa/US06_NEW_PUB.pep:*
- 4: /SIDS5/ptodata/1/pubpaa/US07_NEW_PUB.pep:*
- 5: /SIDS5/ptodata/1/pubpaa/PCT_NEW_PUB.pep:*
- 6: /SIDS5/ptodata/1/pubpaa/US09_NEW_PUB.pep:*
- 7: /SIDS5/ptodata/1/pubpaa/US10_NEW_PUB.pep:*
- 8: /SIDS5/ptodata/1/pubpaa/US11_NEW_PUB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	964.5	75.6	409	6	US-10-503-590A-2	Sequence 2, Appli
2	948	74.3	241	6	US-10-902-546-6	Sequence 6, Appli
3	936	73.4	241	6	US-10-902-546-5	Sequence 5, Appli
4	907	71.1	290	7	US-11-032-773-957	Sequence 957, App
5	907	71.1	319	7	US-11-032-773-955	Sequence 955, App
6	895	70.1	248	6	US-10-512-184-36	Sequence 36, Appl
7	895	70.1	615	6	US-10-512-184-50	Sequence 50, Appl
8	837.5	65.6	543	6	US-10-495-664-3	Sequence 3, Appli
9	832	65.2	237	6	US-10-073-301A-9	Sequence 9, Appli
10	832	65.2	237	7	US-11-203-137-9	Sequence 9, Appli
11	827	64.8	251	7	US-11-054-515-1921	Sequence 1921, Ap
12	827	64.8	251	7	US-11-054-444-1921	Sequence 1921, Ap
13	824.5	64.6	248	7	US-11-054-515-1778	Sequence 1778, Ap
14	824.5	64.6	248	7	US-11-266-444-1778	Sequence 1778, Ap
15	823	64.5	243	6	US-10-537-061-2	Sequence 2, Appli
16	822.5	64.5	250	7	US-11-054-515-932	Sequence 932, App
17	822.5	64.5	250	7	US-11-266-444-932	Sequence 932, App
18	821.5	64.4	248	7	US-11-054-515-1008	Sequence 1008, Ap
19	821.5	64.4	248	7	US-11-266-444-1008	Sequence 1008, Ap
20	819	64.2	245	7	US-11-054-515-1902	Sequence 1902, Ap
21	819	64.2	245	7	US-11-266-444-1902	Sequence 1902, Ap
22	815	63.9	243	7	US-11-054-515-2063	Sequence 2063, Ap
23	815	63.9	243	7	US-11-266-444-2063	Sequence 2063, Ap
24	813.5	63.8	248	7	US-11-054-515-1446	Sequence 1446, Ap
25	813.5	63.8	248	7	US-11-266-444-1446	Sequence 1446, Ap

26	809	63.4	243	6	US-10-537-061-3	Sequence 3, Appli
27	808.5	63.4	248	7	US-11-054-515-1104	Sequence 1104, Ap
28	808.5	63.4	248	7	US-11-266-444-1104	Sequence 1104, Ap
29	808	63.3	241	7	US-11-054-515-1948	Sequence 1948, Ap
30	808	63.3	241	7	US-11-266-444-1948	Sequence 1948, Ap
31	808	63.3	249	7	US-11-054-515-926	Sequence 926, App
32	808	63.3	249	7	US-11-266-444-926	Sequence 926, App
33	808	63.3	277	7	US-11-126-817-54	Sequence 54, Appl
34	804.5	63.0	248	7	US-11-054-515-1771	Sequence 1771, Ap
35	804.5	63.0	248	7	US-11-266-444-1771	Sequence 1771, Ap
36	804	63.0	249	7	US-11-054-515-918	Sequence 918, App
37	804	63.0	249	7	US-11-266-444-918	Sequence 918, App
38	803.5	63.0	248	7	US-11-054-515-1700	Sequence 1700, Ap
39	803.5	63.0	248	7	US-11-266-444-1700	Sequence 1700, Ap
40	803	62.9	249	7	US-11-054-515-919	Sequence 919, App
41	803	62.9	249	7	US-11-266-444-919	Sequence 919, App
42	801	62.8	249	7	US-11-054-515-1635	Sequence 1635, Ap
43	801	62.8	249	7	US-11-266-444-1635	Sequence 1635, Ap
44	800.5	62.7	246	7	US-11-054-515-2062	Sequence 2062, Ap
45	800.5	62.7	246	7	US-11-266-444-2062	Sequence 2062, Ap

ALIGNMENTS

RESULT 1
US-10-503-590A-2
; Sequence 2, Application US/10503590A
; Publication No. US20060062780A1
; GENERAL INFORMATION:
; APPLICANT: ZOCHER, MARCEL
; APPLICANT: DREIER, TORSTEN
; APPLICANT: BAEUERLE, PATRICK
; TITLE OF INVENTION: DE-IMMUNIZED (POLY) PEPTIDE CONSTRUCTS
; FILE REFERENCE: 028622-0134
; CURRENT APPLICATION NUMBER: US/10/503,590A
; PRIOR FILING DATE: 2004-08-12
; PRIOR APPLICATION NUMBER: PCT/EP03/01389
; PRIOR FILING DATE: 2003-02-12
; PRIOR APPLICATION NUMBER: EP 02003332.0
; PRIOR FILING DATE: 2002-02-13
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 2
; LENGTH: 409
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-503-590A-2

Query Match 75.6%; Score 964.5; DB 6; Length 409;
Best Local Similarity 77.3%; Pred. No. 1.5e-56;
Matches 187; Conservative 17; Mismatches 35; Indels 3; Gaps 1;
Cy 3 VQLQSGPELEKPGASVKLSCKASGYSTGYTMNWKQSHGKSLIEWIGLITPYNGASSYN 62
Db 162 IKLQSGAEIARPGASVKMSCKTSGYTFRTYTMHWKQRPQGLEWIGYINPSRGYTNYN 221
Cy 63 OKFRKATLTVDKSSSTAYMDLISLTSSEDAVYFCARGGYDGRGPDYWGQTTVSS-- 120
Db 222 OKFKDKATLTITDKSSSTAYMQLSLTSSEDAVYVCARYDDHYCLDYWGQTTLTVSSVE 281
Cy 121 -GVGSGGGSGSGGSDIELTQSPAIMASPGKVTMTCSASSSVYMHMYQOKSGTSPK 179
Db 282 GSGSGSGSGSGSGGVDDIQLTQSPAIMASPGKVTMTCRASSSVSYNMWYQOKSGTSPK 341
Cy 180 RWIYDTSKLASGVPRFSGSGSNSYSLTISVVEADDATYYCQQWSGYPLTFGAGTKLE 239
Db 342 RWIYDTSKVASGVPRFSGSGSNSYSLTISVMEADDAATYYCQQWSNPLTFGAGTKLE 401
Cy 240 IK 241
Db 402 LK 403


```

; PRIOR APPLICATION NUMBER: 60/536,184
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: 60/557,591
; PRIOR FILING DATE: 2004-03-29
; NUMBER OF SEQ ID NOS: 958
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 955
; LENGTH: 319
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: pBAD S1C5 CD20 His Protein Sequence
US-11-032-773-955

```

Query Match	71.1%;	Score 907;	DB 7;	Length 319;
Best Local Similarity	73.8%;	Pred. No. 6.9e-53;		
Matches 183; Conservative	17;	Mismatches 40;	Indels 8;	Gaps 3;

```
QY 2 QVQLDQSGPELEKPGASVKLSCKASGYSFTGYTMNWVKSHGKSLIEWIGLTIPYNGASSY 61
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 3 EYVQLDQSGAELVKKPGASVKISCKASGYFTDVIHWVKRPEQGLEWIGFISPGNGDIRY 62
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 62 NQKRFKATLTIVDKSSSTAYMDLSTLSEDSAVYFCARG--GYDGRGFDPWGQGTITVTS 119
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 63 NEKFKDKATLTADKSSSTAYMQLNSTLSEDSAVYFCCKSPFYDDNYDNGDWGQGTITLTVS 1222
```

QY 120 S----GVGGSGGGSGGGSDIELTGPALMSASPGKRYMTCSASSV--SYMHWYQOK 173

Db 123 SSGAPGGGGSGGGSGGGSDIVLTGPALMSASLBERYMTCTASSSVSYFHWYQOK 182

QY 174 SGTSPKRWIYDTSKLASGVPRFGSGSGNSYSTLTSSVEAEDDATYYCQOWSGYPPLTFG 233
:
Db 183 PGSSPKLWIYTTSNLSAGVPARFSGSGTYSYSLTISSMEADATYYCHQYHRSPLTFG 242

Qy	234	AGTKLEIK	241
		:	
Db	243	AGTKLEIK	250

RESULT 6

```

; Sequence 36, Application US/10512184
; Publication No. US20050244901A1
; GENERAL INFORMATION:
; APPLICANT: Fraunhofer Gesellschaft zur F"rderung der angewandten Forschung e.V.
; TITLE OF INVENTION: Antibodies, recombinant antibodies, recombinant
; TITLE OF INVENTION: antibody fragments and fusions mediated plant disease
; TITLE OF INVENTION: resistance against fungi
; FILE REFERENCE: 3581.01US01
; CURRENT APPLICATION NUMBER: US/10/512,184
; CURRENT FILING DATE: 2004-10-22
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 36
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: scFv SS2 with
; OTHER INFORMATION: specificity against Sclerotinia sclerotiorum;
; OTHER INFORMATION: originates from Mus musculus.
US-10-512-184-36

```

Query Match	70.1%;	Score 895;	DB 6;	Length 248;
Best Local Similarity	73.1%;	Pred. No. 3.4e-52;		
Matches 179;	Conservative 20;	Mismatches 40;	Indels 6;	Gaps 3;

QY 2 QVQLQSGPELEKRGASVYKLSCKRSGYSFTGYTMNMYKQSHGKSLKLENTGLITPYNGASSY 61
| | | | | : | | | | | : | | | | | : | | | | | : | |
Db 3 QVQLQSGTVLARGASVKMSCKRSGYFTFSYMHWHVQRPGQGLEWIGAIYPGNSPTSY 62
| | | | | : | | | | | : | | | | | : | | | | | : | |
QY 62 NQKRGKATLVYDKSSSTAYMDLSTLSEDSAVYPCARGGYDGRGPDYWGQGTITVYSSG 121
| | | | | : | | | | | : | | | | | : | | | | | : | |

Db	63	NQKFKGAKLTAVTISTSTAYMELSLTNEDSA VYICRTDWD-YAMDYWGCGTSTVTS6G	121
QY	122	-VGSG---GGSGGGGGSDIELTSPAIMSASPGKXTWTCSSASSVSYMHWYQOKSGT	176
Db	122	STSGSGKPPGEGSTKGAPDIVLFGSPVIMSASPGKXTWTCSSASSVNYIYWQOKSGT	181
QY	177	SPKRWIYDTSKLASGVPRFSGSGSGNSYSLTISSVEAEDDATYYCQOMSGYPLTFGAGT	236
Db	182	SPKRWIFDTSKLASGVPRFSGSGSGTSFSLTISSEAEADATYYCQOMSSPPLTFGAGT	241
QY	237	KLEIK 241	
Db	242	KLEIK 246	

```

RESULT 7
US-10-512-184-50
; Sequence 50, Application US/10512184
; Publication No. US20050244901A1
; GENERAL INFORMATION:
; APPLICANT: Fraunhofer Gesellschaft zur F"rderung der angewandten Forschung e.V
; TITLE OF INVENTION: Antibodies, recombinant antibodies, recombinant
; TITLE OF INVENTION: antibody fragments and fusions mediated plant disease
; TITLE OF INVENTION: resistance against fungi
; FILE REFERENCE: 3581.01US01
; CURRENT APPLICATION NUMBER: US/10/512,184
; CURRENT FILING DATE: 2004-10-22
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 50
; LENGTH: 615
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: fusion protein
; OTHER INFORMATION: comprising the leader peptide - chitinase - linker
; OTHER INFORMATION: - scFv SS2 - cmc/His6.
US-10-512-184-50

```

	Query Match	70.1%;	Score 895;	DB 6;	Length 615;	
	Best Local Similarity	73.1%;	Pred. No. 7.4e-52;			
	Matches 179;	Conservative 20;	Mismatches 40;	Indels 6;	Gaps 3;	
<hr/>						
QY	2 QVQLQQSGPELEKPGASVKLSCKASGYFTGVTMNMWVKSHGSKLEWIGLITPYNGASSY	61				
	: : : :					
Dd	344 QVQLQQSGTVLARPGASVTKMSCKASGYFTFSYWMHWKQRPGGLEWIGALYPGNSDTSY	403				
<hr/>						
QY	62 NQFRGKATLTVDKSSSTAYMDLLSLTSEDSAVVFCAARGYDGRGFDYWGCGTTVTVSSG	121				
	: : : :					
Dd	404 NQFKFGKAKLTAVTSTSTAYMELSSLTNEDSAVYYCTRTIMD-YAMDYWGCGTSVTVSSG	462				
<hr/>						
QY	122 -VGSG-----GGSGGGGGSIDIELTQSPAINMASPGEKVMTCSASSSVSYMHMYQQKSGT	176				
Dd	463 STSGSGKPDPGEGSTKGADIVLFQSPVIMSASPGEKVMTCSASSSVNYITYYQWKSGT	522				
<hr/>						
QY	177 SPKRWIYDTSKLASGVPERFSGSGSNGNSYLLTISSVEAEDDATYYCCQWMSGYPLTFGAGT	236				
	: : :					
Dd	523 SPKRWIYDTSKLASGVPRFSGSGSGTISLTISSMEAEADIATYYCQWMSGPPLTFGAGT	582				
<hr/>						
QY	237 KLEIK 241					
	:					
Dd	583 KLEIK 587					

```

RESULT 8
US-10-495-664-3
; Sequence 3, Application US/10495664
; Publication No. US20050244416A1
; GENERAL INFORMATION:
; APPLICANT: JUNG, GUNDRAM
; TITLE OF INVENTION: BISPECIFIC ANTI-CD28 ANTIBODY MOLECULE
; FILE REFERENCE: 034258-0801
; CURRENT APPLICATION NUMBER: US/10/495,664

```

```

; CURRENT FILING DATE: 2004-05-12
; PRIOR APPLICATION NUMBER: PCT/EP02/12545
; PRIOR FILING DATE: 2002-11-09
; PRIOR APPLICATION NUMBER: DE 101 56 482.1
; PRIOR FILING DATE: 2001-11-12
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 3
; LENGTH: 543
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: protein construct
US-10-495-664-3
```

```

Query Match          65.6%; Score 837.5; DB 6; Length 543;
Best Local Similarity 67.6%; Pred. No. 3.9e-48;
Matches 169; Conservative 22; Mismatches 46; Indels 13; Gaps 3;
```

```

QY 2 QVQLQSGPELEKPGASVKLSCKASGYFTGYTMNWVKOSHGKSLIEWIGLITPYNGASSY 61
   ||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 287 QVQLQSGPELVKPGASVKISCKASGYAFSRSMNWYKRPQGLIEWIGRIYPGDPTNY 346
QY 62 NQKFRGKATLTVDKSSSTAYMDLSLTSDSAVYFCARGG-----YDGRGFDYWGQGTIV 116
   ||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 347 NGKFKGKATLTADKSSSTAYMQVSSLTSDSAVYFCARGNTVVVPT---MDYWGQGTIV 403
QY 117 TVSSGVGGSGGGGGSDIELTQSPAIMSAPGEKVTMTCSASSV-----SYMHWYQ 171
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 404 TVSSGGGGSGGGGGSDIELTQSPAILAVSLGQRATISCRASESDVSXGNSFMHWYQ 463
QY 172 QKSGTSPKRWIYDTSKLASGVPRFSGSGSGNSYSLTISVVEAEDDATYYCQQWSGYPLT 231
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 464 QKPGQPPKLLIYLASNLESQVAPRFSGSGSRTDFTLTIDPEADDAATYYCQQNNEDPLT 523
QY 232 FGAGTKLEIK 241
   |||||:|||||:
Db 524 FGGGTLEIK 533
```

```

RESULT 9
US-10-073-301A-9
; Sequence 9, Application US/10073301A
; Publication No. US20050255101A1
; GENERAL INFORMATION:
; APPLICANT: Reiter, Yoram
; APPLICANT: Denkerberg, Galit
; TITLE OF INVENTION: ANTIBODY HAVING A T-CELL RECEPTOR-LIKE SPECIFICITY, YET HIGHER AFFINITY
; TITLE OF INVENTION: AND THE USE OF SAME IN THE DETECTION AND TREATMENT OF CANCER, VI
; TITLE OF INVENTION: AND AUTOIMMUNE DISEASE
; FILE REFERENCE: 01/23094
; CURRENT APPLICATION NUMBER: US/10/073,301A
; CURRENT FILING DATE: 2002-07-02
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 237
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: G1 single chain Fv- recombinant antibody protein sequence
US-10-073-301A-9
```

```

Query Match          65.2%; Score 832; DB 6; Length 237;
Best Local Similarity 65.0%; Pred. No. 4.4e-48;
Matches 154; Conservative 36; Mismatches 47; Indels 0; Gaps 0;
```

```

QY 2 QVQLQSGPELEKPGASVKLSCKASGYFTGYTMNWVKOSHGKSLIEWIGLITPYNGASSY 61
   ||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 1 QVQLQESGGGLVPGGSLKLSCKASGFTFSSYGSMSWVRQTPDKRLIEWATISSGGSYTTY 60
QY 62 NQKFRGKATLTVDKSSSTAYMDLSLTSDSAVYFCARGGYDGRGFDYWGQGTIVTVSSG 121
```

```

Db 61 PDSVKGRFTISRDNAKNTLYLQMSLSKSEDTAMYYCARGNMEGWYFDVWGQGTIVTVSSG 120
   ||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
QY 122 VGGSGGGSGGGSDIELTQSPAIMSAPGEKVTMTCSASSSVSYMHWYQKSGTSPKRW 181
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 121 GGGSGGGSGGGSNIELTQSPAIMSAPGERVTMTCSASSSIRIYMYQKPGSSPRL 180
QY 182 IYDTSKLASGVPRFSGSGSGNSYSLTISVVEAEDDATYYCQQWSGYPLTFAGTKL 238
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 181 IYDTSNVAAPGVPRFSGSGSGTSLTINRMEADDAATYYCQEWSGYPYTFGGGTKL 237
```

```

RESULT 10
US-11-203-137-9
; Sequence 9, Application US/11203137
; Publication No. US20050287141A1
; GENERAL INFORMATION:
; APPLICANT: Reiter, Yoram
; APPLICANT: Denkerberg, Galit
; TITLE OF INVENTION: ANTIBODY HAVING A T-CELL RECEPTOR-LIKE SPECIFICITY, YET HIGHER AFFINITY
; TITLE OF INVENTION: AND THE USE OF SAME IN THE DETECTION AND TREATMENT OF CANCER, VI
; TITLE OF INVENTION: AND AUTOIMMUNE DISEASE
; FILE REFERENCE: 30177
; CURRENT APPLICATION NUMBER: US/11/203,137
; CURRENT FILING DATE: 2005-08-15
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 237
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: G1 single chain Fv- recombinant antibody protein sequence
US-11-203-137-9
```

```

Query Match          65.2%; Score 832; DB 7; Length 237;
Best Local Similarity 65.0%; Pred. No. 4.4e-48;
Matches 154; Conservative 36; Mismatches 47; Indels 0; Gaps 0;
```

```

QY 2 QVQLQSGPELEKPGASVKLSCKASGYFTGYTMNWVKOSHGKSLIEWIGLITPYNGASSY 61
   ||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 1 QVQLQESGGGLVPGGSLKLSCKASGFTFSSYGSMSWVRQTPDKRLIEWATISSGGSYTTY 60
QY 62 NQKFRGKATLTVDKSSSTAYMDLSLTSDSAVYFCARGGYDGRGFDYWGQGTIVTVSSG 121
   ||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 61 PDSVKGRFTISRDNAKNTLYLQMSLSKSEDTAMYYCARGNMEGWYFDVWGQGTIVTVSSG 120
QY 122 VGGSGGGSGGGSDIELTQSPAIMSAPGEKVTMTCSASSSVSYMHWYQKSGTSPKRW 181
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 121 GGGSGGGSGGGSNIELTQSPAIMSAPGERVTMTCSASSSIRIYMYQKPGSSPRL 180
QY 182 IYDTSKLASGVPRFSGSGSGNSYSLTISVVEAEDDATYYCQQWSGYPLTFAGTKL 238
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 181 IYDTSNVAAPGVPRFSGSGSGTSLTINRMEADDAATYYCQEWSGYPYTFGGGTKL 237
```

```

RESULT 11
US-11-054-515-1921
; Sequence 1921, Application US/11054515
; Publication No. US20050255532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunoselectively Bind Bly
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
```

```
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1921
; LENGTH: 251
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-054-515-1921

Query Match          64.8%; Score 827; DB 7; Length 251;
Best Local Similarity 63.2%; Pred. No. 9.8e-48;
Matches 158; Conservative 37; Mismatches 45; Indels 10; Gaps 2;

QY      2 QVQLQSGPELEKPGASVKLSCKASGYSTGYTMNWVKOSHGLTIPYNGASSY 61
Db      1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGMSAYNGNTNY 60

QY      62 NQKFRGKATLTVDKSSSTAYMDLSTLSEDSAVYFCAR-----GGYDGRGFDYWGQ 112
Db      61 AQKLGRTVMTTDTSTSTAYMELRSLRSDDTAVYVCARVTSLSYSSSGGYTYGMDVWGR 120

QY      113 GTTVTVSSGVGSGGGSGGSDIELTQSPAIMSASPEKVTMTCSASSV-SYMHMYQ 171
Db      121 GTTVTVSSGGGSGGGSGGSDIQMTQSPFLSASVGDRTVITCRASQGINNYLAMYQ 180

QY      172 QKSGTSPKRWIYDTSKLASGVPRFSGSGSGNSYSLTSSVEAEDDATYYCQWMSGYPLT 231
Db      181 QKPRAPKLLIYAASSLSQSGVPSRFSGSGSGTDTFTLTISLQPEDPATYYCLQDSDYPLT 240

QY      232 FGAGTKLEIK 241
Db      241 FGGGTKLEIK 250

RESULT 12
US-11-266-444-1921
; Sequence 1921, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulatc
; FILE REFERENCE: PF523PID1
; CURRENT APPLICATION NUMBER: US/11/266,444
; PRIOR FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: Patentln Ver. 2.0
; SEQ ID NO 1921
; LENGTH: 251
; TYPE: PRT
```

```
; ORGANISM: Homo sapiens
; US-11-266-444-1921

Query Match          64.8%; Score 827; DB 7; Length 251;
Best Local Similarity 63.2%; Pred. No. 9.8e-48;
Matches 158; Conservative 37; Mismatches 45; Indels 10; Gaps 2;

QY      2 QVQLQSGPELEKPGASVKLSCKASGYSTGYTMNWVKOSHGLTIPYNGASSY 61
Db      1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGMSAYNGNTNY 60

QY      62 NQKFRGKATLTVDKSSSTAYMDLSTLSEDSAVYFCAR-----GGYDGRGFDYWGQ 112
Db      61 AQKLGRTVMTTDTSTSTAYMELRSLRSDDTAVYVCARVTSLSYSSSGGYTYGMDVWGR 120

QY      113 GTTVTVSSGVGSGGGSGGSDIELTQSPAIMSASPEKVTMTCSASSV-SYMHMYQ 171
Db      121 GTTVTVSSGGGSGGGSGGSDIQMTQSPFLSASVGDRTVITCRASQGINNYLAMYQ 180

QY      172 QKSGTSPKRWIYDTSKLASGVPRFSGSGSGNSYSLTSSVEAEDDATYYCQWMSGYPLT 231
Db      181 QKPRAPKLLIYAASSLSQSGVPSRFSGSGSGTDTFTLTISLQPEDPATYYCLQDSDYPLT 240

QY      232 FGAGTKLEIK 241
Db      241 FGGGTKLEIK 250

RESULT 13
US-11-054-515-1778
; Sequence 1778, Application US/11054515
; Publication No. US20050255532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; PRIOR FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1778
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-054-515-1778

Query Match          64.6%; Score 824.5; DB 7; Length 248;
Best Local Similarity 63.2%; Pred. No. 1.4e-47;
Matches 156; Conservative 37; Mismatches 47; Indels 7; Gaps 2;

QY      2 QVQLQSGPELEKPGASVKLSCKASGYSTGYTMNWVKOSHGLTIPYNGASSY 61
Db      1 QVQLVSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGMSAYNGNTNY 60
```


[illegible]

```

RESULT 14
US-11-266-444-1778
; Sequence 1778, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulatcd
; FILE REFERENCE: PF523PID1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1778
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1778

```

[illegible]

```

RESULT 15
US-10-537-061-2
; Sequence 2, Application US/10537061
; Publication No. US20060051359A1
; GENERAL INFORMATION:
; APPLICANT: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS
; APPLICANT: REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND
; APPLICANT: HUMAN SERVICES
; APPLICANT: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
; APPLICANT: Pastan, Ira
; APPLICANT: Onda, Masanori
; APPLICANT: Cheung, Nai-Kong
; TITLE OF INVENTION: IN-VIVO CYTOTOXIC ACTIVITIES OF RECOMBINANT IMMUNOTOXIN 8H9
; TITLE OF INVENTION: (FV)-PE38 AGAINST BREAST CANCER, OSTEOCARCINOMA AND NEUROBLASTOC
; FILE REFERENCE: 4239-67287-05
; CURRENT APPLICATION NUMBER: US/10/537,061
; CURRENT FILING DATE: 2005-06-01
; PRIOR APPLICATION NUMBER: PCT/US03/038227
; PRIOR FILING DATE: 2003-12-01
; PRIOR APPLICATION NUMBER: US 60/430,305
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 243
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-537-061-2

```

[illegible]

Search completed: April 3, 2006, 05:31:37
Job time : 46 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: April 3, 2006, 05:30:14 ; Search time 23 Seconds
(without alignments)
866.297 Million cell updates/sec

Title: US-09-979-539-1
Perfect score: 1276
Sequence: 1 MOVQLQOQSGPELEKPGASVK.....CQQWSGYPLTFGAGTKLEIK 241

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA:*
1: /cgn2_6/ptodata/1/iaa/5 COMB.pep:*
2: /cgn2_6/ptodata/1/iaa/6 COMB.pep:*
3: /cgn2_6/ptodata/1/iaa/H COMB.pep:*
4: /cgn2_6/ptodata/1/iaa/PCTUS COMB.pep:*
5: /cgn2_6/ptodata/1/iaa/RE COMB.pep:*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1274	99.8	241	2	US-09-581-345-5
2	1010.5	79.2	239	2	US-09-830-954A-6
3	993	77.8	244	1	US-08-553-497A-20
4	987	77.4	242	1	US-08-553-497A-26
5	982.5	77.0	297	2	US-09-486-814A-2
6	981.5	76.9	599	1	US-08-463-163-3
7	979	76.7	244	1	US-08-553-497A-22
8	977	76.6	242	1	US-08-553-497A-28
9	976.5	76.5	239	2	US-08-279-772A-8
10	976.5	76.5	239	2	US-08-902-486-11
11	972	76.2	246	1	US-08-553-497A-24
12	959.5	75.2	256	2	US-09-526-738A-2
13	959.5	75.2	258	2	US-09-526-738A-4
14	956.5	75.0	495	2	US-09-948-004-18
15	908	71.2	238	2	US-09-798-689-21
16	902.5	70.7	246	1	US-08-469-486-57
17	902.5	70.7	246	1	US-08-469-658-57
18	897.5	70.3	264	2	US-10-114-716A-46
19	889.5	69.7	270	1	US-08-652-507-2
20	885.5	69.4	281	2	US-09-423-439-44
21	885.5	69.4	666	2	US-09-423-439-51
22	883.5	69.2	553	1	US-08-661-052-16
23	883.5	69.2	553	2	US-09-188-082-16
24	883.5	69.2	553	2	US-09-364-088-16
25	883.5	69.2	553	2	US-09-102-716-16
26	866	67.9	267	2	US-09-485-737B-2
27	866	67.9	267	2	US-10-071-485-2

28	866	67.9	541	2	US-09-485-737B-85	Sequence 85, Appl
29	866	67.9	541	2	US-10-071-485-85	Sequence 85, Appl
30	866	67.9	711	2	US-09-485-737B-90	Sequence 90, Appl
31	866	67.9	711	2	US-10-071-485-90	Sequence 90, Appl
32	854	66.9	284	2	US-09-184-658-40	Sequence 40, Appl
33	854	66.9	284	2	US-09-504-262D-40	Sequence 40, Appl
34	849.5	66.6	255	2	US-09-553-498-8	Sequence 8, Appli
35	849.5	66.6	255	2	US-09-618-869-8	Sequence 8, Appli
36	841.5	65.9	273	1	US-08-403-853-18	Sequence 18, Appl
37	841	65.9	235	1	US-08-190-199A-61	Sequence 61, Appl
38	839	65.8	267	2	US-09-419-788-30	Sequence 30, Appl
39	834.5	65.4	240	2	US-09-485-737B-91	Sequence 91, Appl
40	834.5	65.4	240	2	US-10-071-485-91	Sequence 91, Appl
41	831.5	65.2	240	1	US-08-800-198-8	Sequence 8, Appli
42	831.5	65.2	240	2	US-09-296-595-8	Sequence 8, Appli
43	829	65.0	288	2	US-09-423-439-38	Sequence 38, Appl
44	829	65.0	673	2	US-09-423-439-32	Sequence 32, Appl
45	823	64.5	260	1	US-08-447-402-1	Sequence 1, Appli

ALIGNMENTS

RESULT 1
US-09-581-345-5
: Sequence 5, Application US/09581345
: Patent No. 6809184
: GENERAL INFORMATION:
: APPLICANT: Pastan, Ira H.
: APPLICANT: Chowdhury, Partha S.
: APPLICANT: The Government of the United States
: APPLICANT: as represented by The Secretary of the
: APPLICANT: Department of Health and Human Services
: TITLE OF INVENTION: Antibodies, including Fv Molecules, and
: TITLE OF INVENTION: Immunconjugates Having High Binding Affinity for
: TITLE OF INVENTION: Mesothelin and Methods for Their Use
: FILE REFERENCE: 015280-339100US
: CURRENT APPLICATION NUMBER: US/09/581,345
: CURRENT FILING DATE: 2000-09-27
: PRIOR APPLICATION NUMBER: US 60/067,175
: PRIOR FILING DATE: 1997-12-01
: PRIOR APPLICATION NUMBER: WO PCT/US98/25270
: PRIOR FILING DATE: 1998-11-25
: NUMBER OF SEQ ID NOS: 9
: SOFTWARE: Patentin Ver. 2.0
: SEQ ID NO 5
: LENGTH: 241
: TYPE: PRT
: ORGANISM: Artificial Sequence
: FEATURE:
: OTHER INFORMATION: Description of Artificial Sequence:SS scFv
US-09-581-345-5

Query Match 99.8%; Score 1274; DB 2; Length 241;
Best Local Similarity 99.6%; Pred. No. 1.3e-95;
Matches 240; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY	1	MOVQLQOQSGPELEKPGASVKLSCKASGYSFTGYTMNWKQSHGKSLWIGLITPYNGASS	60
DB	1	MOVQLQOQSGPELEKPGASVKISCKASGYSFTGYTMNWKQSHGKSLWIGLITPYNGASS	60
QY	61	YNQKRGKATLTVDKSSSTAYMDLSTSEDSAVYFCARGYDGRGFDYWGQGTIVVSS	120
DB	61	YNQKRGKATLTVDKSSSTAYMDLSTSEDSAVYFCARGYDGRGFDYWGQGTIVVSS	120
QY	121	GVGSGGGGSGGGSDILTQSPALMSASPGEKVTMTCSASSSVYMHWYQKSGTSPKR	180
DB	121	GVGSGGGGSGGGSDILTQSPALMSASPGEKVTMTCSASSSVYMHWYQKSGTSPKR	180
QY	181	WIYDTSKLASGVGRFSSGSGNSYSLTISVVEADDATYYCQQWSGYPLTFGAGTKLEI	240
DB	181	WIYDTSKLASGVGRFSSGSGNSYSLTISVVEADDATYYCQQWSGYPLTFGAGTKLEI	240

QY 241 K 241
Db 241 K 241

RESULT 2
US-09-830-954A-6
; Sequence 6, Application US/09830954A
; Patent No. 6919075
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: FRENKEL, Dan
; APPLICANT: HANAN, Bilal
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME USEFUL IN DIAG
; TITLE OF INVENTION: AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES
; FILE REFERENCE: SOLOMON=2C
; CURRENT APPLICATION NUMBER: US/09/830,954A
; CURRENT FILING DATE: 2001-05-03
; PRIOR APPLICATION NUMBER: PCT/IL00/00518
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 239
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-830-954A-6

Query Match 79.2%; Score 1010.5; DB 2; Length 239;
Best Local Similarity 79.8%; Pred. No. 2.8e-74;
Matches 194; Conservative 16; Mismatches 26; Indels 7; Gaps 2;

QY 2 QVQLQSGPELEKPGASVYKLSCKASGYSTGYTMNWVKQSHGKSLWIGLITPYNGASSY 61
Db 1 QVQLQSGAELVPRPGSVYKLSCKGSGYFTFYAMHWVKQSHAKSLWIGISTYYGDASY 60
QY 62 NQKFRGKATLTVDKSSSTAYMDLSTSEDSAVYFCARG--GYDGRGFDYWGQTTVTY 118
Db 61 NQKFKGKATMTVDKSSSTAYMDLSTSEDSALYYCARGLTMSY---FDYWGQVTTVTY 116
QY 119 SSGVGGSGGGGGGGSDIELTQSPAIMSASPEKVTMTCSASSSVSYMHYQOKSGTSP 178
Db 117 SSGGGGGGGGGGGSDIELTQSPAIMSASPEKVTMTCSASSSISYMHYQOKPGTSP 176
QY 179 KRWIYDTSKLASGVPRFSGSGSGNSYSLTSSVEAEDDATYYCCQWMSGYPLTFGAGTKL 238
Db 177 KRWIYDTSKLASGVPRFSGSGSGTSTSLTSSMEADATYYCHQRSSYPTFTFGGAKL 236
QY 239 EIK 241
Db 237 EIK 239

RESULT 3
US-08-553-497A-20
; Sequence 20, Application US/08553497A
; Patent No. 5844093
; GENERAL INFORMATION:
; APPLICANT: KETTLEBOROUGH, C. A.
; APPLICANT: BENDIG, MARY M.
; APPLICANT: ANSELL, KEITH H.
; APPLICANT: GUSSEW, DETLEF
; APPLICANT: ADAN, JAUME
; APPLICANT: MITJANS, FRANCESCA
; APPLICANT: ROSELL, ELISABET
; APPLICANT: BLASCO, FRANCESC
; APPLICANT: PILATS, JAUME

; TITLE OF INVENTION: ANTI-EGFR SINGLE-CHAIN FVS AND ANTI-EGFR
; TITLE OF INVENTION: ANTIBODIES
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
; STREET: 2200 CLARENDON BLVD. SUITE 1400
; CITY: ARLINGTON
; STATE: VA
; COUNTRY: US
; ZIP: 22201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/553,497A
; FILING DATE: 17-NOV-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: WO PCT/EP95/00978
; FILING DATE: 16-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 94104160.0
; FILING DATE: 17-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 94118970.6
; FILING DATE: 02-DEC-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: HAMLET-KING, DIANA
; REGISTRATION NUMBER: 33,302
; REFERENCE/DOCKET NUMBER: MERCK 1726
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-243-6333
; TELEFAX: 703-243-6410
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 244 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-553-497A-20

Query Match 77.8%; Score 993; DB 1; Length 244;
Best Local Similarity 79.9%; Pred. No. 7.4e-73;
Matches 195; Conservative 14; Mismatches 31; Indels 4; Gaps 2;

QY 2 QVQLQSGPELEKPGASVYKLSCKASGYSTGYTMNWVKQSHGKSLWIGLITPYNGASSY 61
Db 1 EVQLQSGAELVPRPGSVYKLSCKASGYFTFSHWKQSHGKSLWIGLITPYNGASSY 60
QY 62 NQKFRGKATLTVDKSSSTAYMDLSTSEDSAVYFCARG--GYDGRGFDYWGQTTVTY 119
Db 61 NEKFRKATLTVDKSSSTAYMDLSTSEDSAVYFCASRDYDGRYFDYWGQTTVTY 120
QY 120 SGVGGSGGGGGGGSDIELTQSPAIMSASPEKVTMTCSASSSVSYMHYQOKSGTSPK 179
Db 121 SGGGGGGGGGGGGSDIELTQSPAIMSASPEKVTMTCSASSSVSYMHYQOKPGSSPR 180
QY 180 RWIYDTSKLASGVPRFSGSGSGNSYSLTSSVEAEDDATYYCCQWMSGYPLTFGAGTK 237
Db 181 LLIYDTSNLASGVPRFSGSGSGTSTSLTSSMEADATYYCCQWMSGYPLTFGAGTK 240
QY 238 LEIK 241
Db 241 LEIK 244

RESULT 4
US-08-553-497A-26
; Sequence 26, Application US/08553497A
; Patent No. 5844093
; GENERAL INFORMATION:

APPLICANT: KETTLERBOROUGH, C. A.
APPLICANT: BENDIG, MARY M.
APPLICANT: ANSELL, KEITH H.
APPLICANT: GUSSEW, DETLEF
APPLICANT: ADAM, JAUME
APPLICANT: MITJANS, FRANCESC
APPLICANT: ROSELL, ELISABET
APPLICANT: BLASCO, FRANCESC
APPLICANT: PIULATS, JAUME
TITLE OF INVENTION: ANTI-EGFR SINGLE-CHAIN FVS AND ANTI-EGFR
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
STREET: 2200 CLARENDON BLVD. SUITE 1400
CITY: ARLINGTON
STATE: VA
COUNTRY: US
ZIP: 22201
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/553,497A
FILING DATE: 17-NOV-1995
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: WO PCT/EP95/00978
FILING DATE: 16-MAR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 94104160.0
FILING DATE: 17-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 94118970.6
FILING DATE: 02-DEC-1994
ATTORNEY/AGENT INFORMATION:
NAME: HAMLET-KING, DIANA
REGISTRATION NUMBER: 33,302
REFERENCE/DOCKET NUMBER: MERCK 1726
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-243-6333
TELEFAX: 703-243-6410
INFORMATION FOR SEQ ID NO: 26:
SEQUENCE CHARACTERISTICS:
LENGTH: 242 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-553-497A-26

Query Match 77.4%; Score 987; DB 1; Length 242;
Best Local Similarity 79.3%; Pred. No. 2.2e-72;
Matches 192; Conservative 16; Mismatches 32; Indels 2; Gaps 1;

QY 2 QVQLQSGPELEKPGASVYKLSCKASGYSTGYTMNWVKQSHGKSLWIGLITPYNGASSY 61
Db 1 QVKLQESGAEIVKPGASVYKLSCKASGYSTGYTMNWVKQSHGKSLWIGLITPYNGASSY 60

QY 62 NQKFRGKATLTVDKSSSTAYMDLSLTSEDSAVYFCARG--GYDGRGPDYWGQGTIVYS 119
Db 61 NEKFKSKATLTVDKSSSTAYMDLSLTSEDSAVYFCASRDYDGRYFDYWGQGTIVYS 120

QY 120 SGVGGSGGGSGGGSDIELTQSPAIMASPGKVTMTCSASSSVSYMHVYQOKSGTSPK 179
Db 121 SGGGSGGGSGGGSDIELTQSPAIMASPGKVTMTCSASSSVSYMHVYQOKSGTSPK 180

QY 180 RWIYDTSKLASGVPRFGSGGSGNSYSLTSSVEAEDDATYCCQWMSGYPLTFGAGTKLE 239
Db 181 LLIYDTSNLAAGVPRFGSGGSGTSTSLTSMEAEDDATYCCQWMSGYPLTFGAGTKLE 240

QY 240 IK 241

Db 241 IK 242

RESULT 5
US-09-486-814A-2
Sequence 2, Application US/09486814A
Patent No. 6562599
GENERAL INFORMATION:
APPLICANT: YAMAMOTO, Masato
APPLICANT: HAYASHI, No. 6562599io
APPLICANT: YAMAMOTO, Hiroko
APPLICANT: TOHDOH, Naoki
TITLE OF INVENTION: SINGLE-CHAIN ANTIBODY AGAINST HEPATITIS B VIRUS CORE
TITLE OF INVENTION: PROTEIN, GENE THEREOF, AND THERAPEUTIC AGENT FOR
FILE REFERENCE: 0020-4682P
CURRENT APPLICATION NUMBER: US/09/486,814A
CURRENT FILING DATE: 2002-06-13
NUMBER OF SEQ ID NOS: 14
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 2
LENGTH: 297
TYPE: PRT
ORGANISM: Mus sp., strain: Balb/c, tissue: spleen
FEATURE:
NAME/KEY: PEPTIDE
LOCATION: (1)..(145)
OTHER INFORMATION: Identification Method: P
FEATURE:
NAME/KEY: PEPTIDE
LOCATION: (177)..(279)
OTHER INFORMATION: Identification Method: P
US-09-486-814A-2

Query Match 77.0%; Score 982.5; DB 2; Length 297;
Best Local Similarity 78.7%; Pred. No. 6.6e-72;
Matches 192; Conservative 15; Mismatches 28; Indels 9; Gaps 3;

QY 2 QVQLQSGPELEKPGASVYKLSCKASGYSTGYTMNWVKQSHGKSLWIGLITPYNGASSY 61
Db 40 QVKLQESGPELEKPGASVYKLSCKASGYSTGYTMNWVKQSHGKSLWIGLITPYNGASSY 99

QY 62 NQKFRGKATLTVDKSSSTAYMDLSLTSEDSAVYFCARGGYDGRGPDYWGQGTIVYSSG 121
Db 100 NQKFKSKATLTVDKSSSTAYMDLSLTSEDSAVYFCAR-----LGLDYWGQGTIVYSSG 154

QY 122 VGGSGGGSGGGSDIELTQSPAIMASPGKVTMTCSASSSV--YMHVYQOKSGTSPK 179
Db 155 GGGSGGGSGGGSDIELTQSPAIMASPGKVTMTCSASSSV--YMHVYQOKSGTSPK 214

QY 180 RWIYDTSKLASGVPRFGSGGSGNSYSLTSSVEAEDDATYCCQWMSGYPLTFGAGTK 237
Db 215 LLIYDTSNLAAGVPRFGSGGSGTSTSLTSMEAEDDATYCCQWMSGYPLTFGAGTK 274

QY 238 LEIK 241
Db 275 LEIK 278

RESULT 6
US-08-463-163-3
Sequence 3, Application US/08463163
Patent No. 5696237
GENERAL INFORMATION:
APPLICANT: Fitzgerald, David J.
APPLICANT: Chaudhary, Vijay K.
APPLICANT: Pastan, Ira H.
APPLICANT: Waldmann, Thomas A.
APPLICANT: Queen, Cary L.
TITLE OF INVENTION: Recombinant Antibody-Toxin Fusion Protein
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:

ADDRESSEE: Townsend and Townsend and Crew
STREET: One Market Plaza, Steuart Street Tower
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94105-1492
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/463,163
FILING DATE: 05-JUN-1995
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 06/227,227
FILING DATE: 22-JAN-1981
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 06/911,227
FILING DATE: 24-SEP-1986
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/341,361
FILING DATE: 21-APR-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/865,722
FILING DATE: 08-APR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Weber, Ellen L.
REGISTRATION NUMBER: 32,762
REFERENCE/DOCKET NUMBER: 015280-12211
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 543-9600
TELEFAX: (415) 543-5043
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 599 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-463-163-3

Query Match 76.9%; Score 981.5; DB 1; Length 599;
Best Local Similarity 78.8%; Pred. No. 1.8e-71;
Matches 190; Conservative 14; Mismatches 34; Indels 3; Gaps 1;
QY 1 MOVOLQSGPELEKPGASVKLSCKASGYSTGYTMNWVKQSHGKSLIEWIGLITPYNGASS 60
DB 1 MOVOLQSGAEIAKPGASVKNKSCASGYTFTSYRMHWVKQRPQGLEWIGYINPSTGYTE 60
QY 61 YNOKFRKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGYDGRGFDYWGQGTITVTVSS 120
DB 61 YNOKFKDKATLTADKSSSTAYMDLLSLTFEDSAVYYCARG--GGVFDYWGQGTITLVSS 117
QY 121 GVGSGSGGGGGGGSDIELTQSPAIMASAPGEKVTMTCSASSSVSYMHVYQOKSGTSPKR 180
DB 118 GGGGSGGGGGGGGQIVLTQSPAIMASAPGEKVTITCSASSSISYMHVFOOKPCTSPKL 177
QY 181 WIYDTSKLASGVPRFSGSGSGNSYSLTISVVEADDAITYYCCQWMSGYPILTFGAGTKLEI 240
DB 178 WIYTTSNLASGVPRFSGSGSGTSTSLTISRMEADDAITYYCHORSTYPLTFGSGTKLEL 237
QY 241 K 241
DB 238 K 238

RESULT 7
US-08-553-497A-22
Sequence 22, Application US/08553497A
Patent No. 5844093
GENERAL INFORMATION:
APPLICANT: KETTLERBOROUGH, C. A.

APPLICANT: BENDIG, MARY M.
APPLICANT: ANSELL, KEITH H.
APPLICANT: GUSSOW, DETLEF
APPLICANT: ADAN, JAUME
APPLICANT: MITJANS, FRANCESCA
APPLICANT: ROSELL, ELISABET
APPLICANT: BLASCO, FRANCESCA
APPLICANT: PILATS, JAUME
TITLE OF INVENTION: ANTI-EGFR SINGLE-CHAIN FVS AND ANTI-EGFR
TITLE OF INVENTION: ANTIBODIES
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
STREET: 2200 CLARENDON BLVD. SUITE 1400
CITY: ARLINGTON
STATE: VA
COUNTRY: US
ZIP: 22201
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/553,497A
FILING DATE: 17-NOV-1995
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: WO PCT/EP95/00978
FILING DATE: 16-MAR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 94104160.0
FILING DATE: 17-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 94118970.6
FILING DATE: 02-DEC-1994
ATTORNEY/AGENT INFORMATION:
NAME: HAMLET-KING, DIANA
REGISTRATION NUMBER: 33,302
REFERENCE/DOCKET NUMBER: MERCK 1726
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-243-6333
TELEFAX: 703-243-6410
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 244 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-553-497A-22

Query Match 76.7%; Score 979; DB 1; Length 244;
Best Local Similarity 78.7%; Pred. No. 1e-71;
Matches 192; Conservative 15; Mismatches 33; Indels 4; Gaps 2;
QY 2 QVQLQSGPELEKPGASVKLSCKASGYSTGYTMNWVKQSHGKSLIEWIGLITPYNGASSY 61
DB 1 EVQLQSGAEIAKPGASVKNKSCASGYTFTSHHWVKQRPAGGLEWIGEFNPSGRTNY 60
QY 62 NOKFRKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARG--GYDGRGFDYWGQGTITVTVS 119
DB 61 NEKIKSKATLTVDKSSSTAYMDLLSLTSEDSAVYFCASRDYDGRYFDYWGQGTITVTVS 120
QY 120 SGVGSGGGGGGGGGSDIELTQSPAIMASAPGEKVTMTCSASSSVSYMHVYQOKSGTSPK 179
DB 121 SGGGSGGGGGGGGGSDIELTQSPAIMASAPGEKVTMTCSASSSVSYMYWYQOKTSSPR 180
QY 180 RWIYDTSKLASGVPRFSGSGSGNSYSLTISVVEADDAITYYCCQWMSGYP--LTFGAGTK 237
DB 181 LLTYDTSNLASGVPRFSGSGSGTSTSLTISRMEADDAITYYCCQWSSYPPMYTFGGGK 240
QY 238 LEIK 241
|||

Db 241 LEIK 244

RESULT 8

US-08-553-497A-28

; Sequence 28, Application US/08553497A

; Patent No. 5844093

; GENERAL INFORMATION:

; APPLICANT: KETTLERBOROUGH, C. A.

; APPLICANT: BENDIG, MARY M.

; APPLICANT: ANSELL, KEITH H.

; APPLICANT: GUSSEW, DETLEF

; APPLICANT: ADAN, JAUME

; APPLICANT: MITJANS, FRANCES

; APPLICANT: ROSELL, ELISABET

; APPLICANT: BLASCO, FRANCESC

; APPLICANT: PUJATS, JAUME

; TITLE OF INVENTION: ANTI-EGFR SINGLE-CHAIN FVS AND ANTI-EGFR

; TITLE OF INVENTION: ANTIBODIES

; NUMBER OF SEQUENCES: 30

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

; STREET: 2200 CLARENDON BLVD. SUITE 1400

; CITY: ARLINGTON

; STATE: VA

; COUNTRY: US

; ZIP: 22201

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patent in Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/553,497A

; FILING DATE: 17-NOV-1995

; CLASSIFICATION: 530

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: WO PCT/EP95/00978

; FILING DATE: 16-MAR-1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: EP 94104160.0

; FILING DATE: 17-MAR-1994

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: EP 94118970.6

; FILING DATE: 02-DEC-1994

; ATTORNEY/AGENT INFORMATION:

; NAME: HAMLET-KING, DIANA

; REGISTRATION NUMBER: 33,302

; REFERENCE/DOCKET NUMBER: MERCK 1726

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 703-243-6333

; TELEFAX: 703-243-6410

; INFORMATION FOR SEQ ID NO: 28:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 242 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: protein

; US-08-553-497A-28

Query Match 76.6%; Score 977; DB 1; Length 242;

Best Local Similarity 78.1%; Pred. No. 1.4e-71;

Matches 189; Conservative 19; Mismatches 32; Indels 2; Gaps 1;

```
OY 2 QVQLQSGPELEKPGASVSKASGYSTGYTMNWVKQSHGKSLIEWIGLITPYNGASSY 61
Db 1 EVKLQSGAELEKPGASVSKASGYSTGYTMNWVKQSHGKSLIEWIGLITPYNGASSY 60
OY 62 NQKFRGKATLTVDKSSSTAYMDLSTSEDSAVYFCARG--GYDGRGPDYWGQGTIVYS 119
Db 61 NEKFKSKATLTVDKSSSTAYIELSLTSEDCSVYYCASRDYDYGRIFDYWGQGTIVYS 120
OY 120 SGVGGSGGGGGGGSDIELTQSPAIMSASPGKVTMTCSASSSVSYMHYIQOKSGTSPK 179
```

```
Db 121 SGGGGSGGGGGGGSDIELTQSPAIMSASPGKVTMTCSASSSVSYMHYIQOKSGTSPK 180
OY 180 RWIYDTSKLASGVPGRFSGSGSGNSYSLTISVVEADDAATYYCCQWGSYPLTFGAGTKLE 239
Db 181 LLIVDTSNLASGVPGRFSGSGSGTSLTISRMEADDAATYYCCQWGSYPLTFGAGTKLE 240
```

OY 240 IK 241

Db 241 IK 242

RESULT 9

US-08-279-772A-8

; Sequence 8, Application US/08279772A

; Patent No. 6080560

; GENERAL INFORMATION:

; APPLICANT: Russell, David R

; APPLICANT: Fuller, James T

; TITLE OF INVENTION: Method for Producing Antibodies in Plant

; TITLE OF INVENTION: Cells

; NUMBER OF SEQUENCES: 9

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Quarles and Brady

; STREET: PO Box 2113

; CITY: Madison

; STATE: WI

; COUNTRY: United States of America

; ZIP: 53701-2113

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patent in Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/279,772A

; FILING DATE:

; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:

; NAME: Seay, Nicholas J.

; REGISTRATION NUMBER: 27,386

; REFERENCE/DOCKET NUMBER: 11-229-9097-1

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 608-251-5000

; TELEFAX: 608-251-9166

; INFORMATION FOR SEQ ID NO: 8:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 239 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: protein

; US-08-279-772A-8

Query Match 76.5%; Score 976.5; DB 2; Length 239;

Best Local Similarity 78.8%; Pred. No. 1.6e-71;

Matches 189; Conservative 14; Mismatches 34; Indels 3; Gaps 1;

```
OY 2 QVQLQSGPELEKPGASVSKASGYSTGYTMNWVKQSHGKSLIEWIGLITPYNGASSY 61
Db 3 QVQLQSGAELEKPGASVSKASGYSTGYTMNWVKQSHGKSLIEWIGLITPYNGASSY 62
OY 62 NQKFRGKATLTVDKSSSTAYMDLSTSEDSAVYFCARGGYDGRGPDYWGQGTIVYS 121
Db 63 NQKFRGKATLTVDKSSSTAYMDLSTSEDSAVYFCARG--GGVFDYWGQGTIVYS 119
OY 122 VGGSGGGSGGGSDIELTQSPAIMSASPGKVTMTCSASSSVSYMHYIQOKSGTSPK 181
Db 120 GGGSGGGSGGGSDIELTQSPAIMSASPGKVTMTCSASSSVSYMHYIQOKSGTSPK 179
OY 182 IYDTSKLASGVPGRFSGSGSGNSYSLTISVVEADDAATYYCCQWGSYPLTFGAGTKLE 241
Db 180 IYDTSKLASGVPGRFSGSGSGTSLTISRMEADDAATYYCHQRTYPLTFGAGTKLE 239
```

```

RESULT 10
US-08-902-486-11
; Sequence 11, Application US/08902486
; Patent No. 6140075
GENERAL INFORMATION:
APPLICANT: Russel, David R.
APPLICANT: Fuller, James T.
TITLE OF INVENTION: METHOD FOR PRODUCING ANTIBODIES AND
TITLE OF INVENTION: PROTEIN TOXINS IN PLANT CELLS
NUMBER OF SEQUENCES: 15
CORRESPONDENCE ADDRESS:
ADDRESSEE: Quarles & Brady
STREET: 1 South Pinckney Street
CITY: Madison
STATE: WI
COUNTRY: US
ZIP: 53701-2113
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/902,486
FILING DATE:
CLASSIFICATION: 800
ATTORNEY/AGENT INFORMATION:
NAME: Seay, Nicholas J.
REGISTRATION NUMBER: 27386
REFERENCE/DOCKET NUMBER: 670513.90261
TELECOMMUNICATION INFORMATION:
TELEPHONE: 608-251-5000
TELEFAX: 608-251-9166
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 239 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-902-486-11

Query Match          76.5%; Score 976.5; DB 2; Length 239;
Best Local Similarity 78.8%; Pred. No. 1.6e-71;
Matches 189; Conservative 14; Mismatches 34; Indels 3; Gaps 1

QY      2 QVQLQQSGPELEKPGASVKLSCKAGSYFTGYTMNWKQSHGKSLIEWIGLITPYNGASSY 61
        ||||| | | | | | | | | | | : | | | | | : | | | | | : |
Db      3 QVQLQQSGAELAKPGASVSKSCASKASYFTTSYRMHWKQRPQGLEGWIGYNPSTGYTEY 62
        ||||| | | | | | | | | | | : | | | | | : | | | | | : |
QY      62 NQKFRGKATLTVDKSSSTAYMDLLTSEDSAVVFCAFGYGDRGFYWGGTTTVSSG 121
        ||||| | | | | | | | | | | : | | | | | : | | | | | : |
Db      63 NQKFXDKATLTADKSSSTAYMLSSLTFEDSAVVYCARG--GGVFYWGQGTTLTVSSG 119
        ||||| | | | | | | | | | | : | | | | | : | | | | | : |
QY      122 VGSGGGGSGGGSDIELTQSPAIMSAPGEKVMTWCSSSSVSVMHWYQOKSGTPRRW 181
        ||||| | | | | | | | | | | : | | | | | : | | | | | : |
Db      120 GGGSGGGSGGGGSGIYLVTQSPAIMASPGEKVTITCSASSISYMWFQOKPGTSPKLW 179
        ||||| | | | | | | | | | | : | | | | | : | | | | | : |
QY      182 IYDTSKLASGVPRFSGSGSGNSYSLTISSVEAEDDATYYCCQWMSGYPLTFGAGTKLEIK 241
        ||||| | | | | | | | | | | : | | | | | : | | | | | : |
Db      180 IYTTSNLASGVPARFSGSGSGTYSLTISRMEADATYYCHQRSTYPLTFGSGTKLELK 239

```

```

1  APPLICANT:  MITJANS, FRANCES C
2  APPLICANT:  ROSELL, ELISABET
3  APPLICANT:  BLASCO, FRANCES C
4  APPLICANT:  PILATS, JAUME
5  TITLE OF INVENTION:  ANTI-EGFR SINGLE-CHAIN FVS AND ANTI-EGFR
6  TITLE OF INVENTION:  ANTIBODIES
7  NUMBER OF SEQUENCES:  30
8  CORRESPONDENCE ADDRESS:
9  ADDRESSEE:  MILLER, WHITE, ZELANO & BRANIGAN, P.C.
10 STREET:  2200 CLARENDON BLVD. SUITE 1400
11 CITY:  ARLINGTON
12 STATE:  VA
13 COUNTRY:  US
14 ZIP:  22201
15
16 COMPUTER READABLE FORM:
17 MEDIUM TYPE:  Floppy disk
18
19 COMPUTER:  IBM PC compatible
20 OPERATING SYSTEM:  PC-DOS/MS-DOS
21 SOFTWARE:  PatentIn Release #1.0, Version #1.30
22
23 CURRENT APPLICATION DATA:
24 APPLICATION NUMBER:  US/08/553,497A
25 FILING DATE:  17-NOV-1995
26
27 CLASSIFICATION:  530
28
29 PRIOR APPLICATION DATA:
30 APPLICATION NUMBER:  WO PCT/EP95/00978
31 FILING DATE:  16-MAR-1995
32
33 PRIOR APPLICATION DATA:
34 APPLICATION NUMBER:  EP 94104160.0
35 FILING DATE:  17-MAR-1994
36
37 PRIOR APPLICATION DATA:
38 APPLICATION NUMBER:  EP 94118970.6
39 FILING DATE:  02-DEC-1994
40
41 ATTORNEY/AGENT INFORMATION:
42 NAME:  HAMLET-KING, DIANA
43 REGISTRATION NUMBER:  33,302
44 REFERENCE/DOCKET NUMBER:  MERCK 1726
45 TELECOMMUNICATION INFORMATION:
46 TELEPHONE:  703-243-6333
47 TELEFAX:  703-243-6410
48
49 INFORMATION FOR SEQ ID NO:  24:
50 SEQUENCE CHARACTERISTICS:
51 LENGTH:  246 amino acids
52 TYPE:  amino acid
53 TOPOLOGY:  linear
54 MOLECULE TYPE:  protein
55
56 US-08-553-497A-24

```

RESULT 11
US-08-553-497A-24
; Sequence 24, Application US/08553497A
; Patent No. 5844093
; GENERAL INFORMATION:
; APPLICANT: KETTLEBOROUGH, C. A.
; APPLICANT: BENDIG, MARY M.
; APPLICANT: ANSELL, KEITH H.
; APPLICANT: GUNSSON, DETLEF
; APPLICANT: ADAN, JAUME

	Query Match	76.2%;	Score 972;	DB 1;	Length 246;	
	Best Local Similarity	78.5%;	Pred. No. 3.7e-71;			
	Matches 193;	Conservative 14;	Mismatches 33;	Indels 6;	Gaps 3;	
Oy	2 QVQLQSGPELEKPGASVKLSCKASGYFTGTMNWVKQSHGKSLIEWIGLITPYNGASSY	61	:	:	:	:
Dd	1 EVQLQQSGAEIVKPGASVKLSCKASGYFTFSHMHMWKQRAQGGLWIGEFNPSNGRTNY	60	:	:	:	:
Oy	62 NQFRGKATLTVDKSSSTAYMDLLSTSEDSAVFYFCARG--GYDGRGFYWGQTTVTS	119	:	:	:	:
Dd	61 NEKFASKATLTVDKSSSTAYMQLSLLTSEDSAVIYYCASRDYDYDGRYFDYWGGTTVTVS	120	:	:	:	:
Oy	120 SGVGSGSGSGSGSG--GSDIELLTQSPAIMSASPGEKVMTTCSSASSSVSYHMVYQOKSGTS	177	:	:	:	:
Dd	121 SGGGSGSGSGSGSGSGSDIELLTQSPTIMSASPGEKVMTCCSDSSSVSYMYVYQOKPSS	180	:	:	:	:
Oy	178 PKRWIYDTSKLASGVPRFSGSGSGNSYSLLTISSVEAEDDATYYCCQOWSGYP--LTFGAG	235	:	:	:	:
Dd	181 PRLLIYDTSNLASGVPRFSGSGSGTYSLLISRMEADDAITYYCQOWSSYIPPMYTFGGG	240	:	:	:	:
Oy	236 TKLEIK 241		:	:	:	:
Dd	241 TKLEIK 246		:	:	:	:


```
US-09-526-738A-2
; Sequence 2, Application US/09526738A
; Patent No. 6630584
; GENERAL INFORMATION:
; APPLICANT: RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT
; APPLICANT: LTD.
; TITLE OF INVENTION: SINGLE CHAIN ANTIBODY AGAINST MUTANT P53
; FILE REFERENCE: 1196336
; CURRENT APPLICATION NUMBER: US/09/526,738A
; CURRENT FILING DATE: 2000-03-16
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 256
; TYPE: PRT
; ORGANISM: Humanus
US-09-526-738A-2

Query Match          75.2%; Score 959.5; DB 2; Length 256;
Best Local Similarity 77.6%; Pred. No. 4e-70;
Matches 187; Conservative 13; Mismatches 36; Indels 5; Gaps 2;

QY 2 QVQLQSGPELEKPGASVKISCKASGYSTGYTMNWVKSHGKSLRWIGLITPYNGASSY 61
DB 1 QVQLQSGAEIAPGASVMSCKTSGYFTSYMMNWVKQRPQGGLRWIGYINPTTGYTKY 60

QY 62 NQKFRGKATLTVDKSSSTAYMDLSTLSEDSAVVFCARG-GYDGRGFDYWGQGTITVSS 120
DB 61 NQKFKDKATLTADKSSSTAYMQLSLTNVDSAVVYCTTGYSY----FDYWGQGTITVSS 116

QY 121 GVGSGGGGGGGGGSDIELTQSPAIMSAPGEKVTMTCSASSSVSYMHVYQOKSGTSPKR 180
DB 117 GGGSGGGGGGGGGSDIELTQSPAIMSAPGEKVTITCSASSSVNYMHVYQOKPGTSPKL 176

QY 181 WIYDTSKLASGVPRFSGSGSGNSYSTLTSSVEAEDDATYCCQWMSGYPLTFGAGTKLEI 240
DB 177 WISTSNLASGVPARFSGSGSGTSTLTSSVEAEDDATYCCQWMSGYPLTFGAGTKLEI 236

QY 241 K 241
DB 237 K 237

RESULT 13
US-09-526-738A-4
; Sequence 4, Application US/09526738A
; Patent No. 6630584
; GENERAL INFORMATION:
; APPLICANT: RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT
; APPLICANT: LTD.
; TITLE OF INVENTION: SINGLE CHAIN ANTIBODY AGAINST MUTANT P53
; FILE REFERENCE: 1196336
; CURRENT APPLICATION NUMBER: US/09/526,738A
; CURRENT FILING DATE: 2000-03-16
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 258
; TYPE: PRT
; ORGANISM: Humanus
US-09-526-738A-4

Query Match          75.2%; Score 959.5; DB 2; Length 258;
Best Local Similarity 77.6%; Pred. No. 4.1e-70;
Matches 187; Conservative 13; Mismatches 36; Indels 5; Gaps 2;

QY 2 QVQLQSGPELEKPGASVKISCKASGYSTGYTMNWVKSHGKSLRWIGLITPYNGASSY 61
DB 3 QVQLQSGAEIAPGASVMSCKTSGYFTSYMMNWVKQRPQGGLRWIGYINPTTGYTKY 62

QY 62 NQKFRGKATLTVDKSSSTAYMDLSTLSEDSAVVFCARG-GYDGRGFDYWGQGTITVSS 120
DB 63 NQKFKDKATLTADKSSSTAYMQLSLTNVDSAVVYCTTGYSY----FDYWGQGTITVSS 118
```

```
QY 121 GVGSGGGGGGGGGSDIELTQSPAIMSAPGEKVTMTCSASSSVSYMHVYQOKSGTSPKR 180
DB 119 GGGSGGGGGGGGGSDIELTQSPAIMSAPGEKVTITCSASSSVNYMHVYQOKPGTSPKL 178

QY 181 WIYDTSKLASGVPRFSGSGSGNSYSTLTSSVEAEDDATYCCQWMSGYPLTFGAGTKLEI 240
DB 179 WISTSNLASGVPARFSGSGSGTSTLTSSVEAEDDATYCCQWMSGYPLTFGAGTKLEI 238

QY 241 K 241
DB 239 K 239

RESULT 14
US-09-948-004-18
; Sequence 18, Application US/09948004
; Patent No. 6723538
; GENERAL INFORMATION:
; APPLICANT: MACK, Mathias
; TITLE OF INVENTION: Antibody and/or chemokine constructs and their use in
; FILE REFERENCE: E 2411 EP
; CURRENT APPLICATION NUMBER: US/09/948,004
; CURRENT FILING DATE: 2001-09-05
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
; LENGTH: 495
; TYPE: PRT
; ORGANISM: Mus sp.
US-09-948-004-18

Query Match          75.0%; Score 956.5; DB 2; Length 495;
Best Local Similarity 76.9%; Pred. No. 1.5e-69;
Matches 186; Conservative 17; Mismatches 36; Indels 3; Gaps 1;

QY 3 VQLQSGPELEKPGASVKISCKASGYSTGYTMNWVKSHGKSLRWIGLITPYNGASSYN 62
DB 248 IKLQSGAEIAPGASVMSCKTSGYFTFRTYTMHWKQRPQGGLRWIGYINPSRGTYNYN 307

QY 63 QKPRGKATLTVDKSSSTAYMDLSTLSEDSAVVFCARGGYDGRGFDYWGQGTITVSS-- 120
DB 308 QKPRDKATLTVDKSSSTAYMQLSLTSEDSAVVYCARYYDDHYCLDYWRQGTITVSSVE 367

QY 121 -GVGSGGGGGGGGGSDIELTQSPAIMSAPGEKVTMTCSASSSVSYMHVYQOKSGTSPK 179
DB 368 GGSGGSGGGGGGGVDIQLTQSPAIMSAPGEKVTMTCRASSSVSYMMWYQOKSGTSPK 427

QY 180 RWIYDTSKLASGVPRFSGSGSGNSYSTLTSSVEAEDDATYCCQWMSGYPLTFGAGTKLE 239
DB 428 RWIYDTSKVASGVPRFSGSGSGTSTLTSSVEAEDDATYCCQWMSGYPLTFGAGTKLE 487

QY 240 IK 241
DB 488 LK 489

RESULT 15
US-09-798-689-21
; Sequence 21, Application US/09798689
; Patent No. 6811779
; GENERAL INFORMATION:
; APPLICANT: Rockwell, Patricia
; APPLICANT: Goldstein, Neil I.
; TITLE OF INVENTION: Method for Reducing Tumor Growth with VEGF Antagonists
; FILE REFERENCE: Sequence Listings 1-41 for 381-25 CIP
; CURRENT APPLICATION NUMBER: US/09/798,689
; CURRENT FILING DATE: 2001-03-02
; PRIOR APPLICATION NUMBER: 09/401,163
; PRIOR FILING DATE: 1999-09-22
```

